

NCI

---

# FACT BOOK

**National  
Cancer  
Institute**

2000

**U.S. DEPARTMENT  
OF HEALTH AND  
HUMAN SERVICES**

**Public Health Service**

**National Institutes of Health**

---

The information set forth in this publication is compiled and amended annually by the financial management staff of the National Cancer Institute and is intended primarily for use by members of the Institute, principal advisory groups to the Institute and others involved in the administration and management of the National Cancer Program. Questions regarding any of the information contained herein may be directed to the Financial Management Branch, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland, 20892.

# TABLE OF CONTENTS

<b>Executive Summary</b>	.....	iii
<b>Organization</b>	Director's Biography ..... O-1 Former Directors of the NCI ..... O-2 National Cancer Advisory Board..... O-3 Boards of Scientific Counselors and Advisors..... O-7 President's Cancer Panel..... O-8 Executive Committee Members ..... O-8 Organization Charts: National Cancer Institute..... O-9 Office of the Director..... O-10 OD I: Office of Management..... O-11 OD II: Office of the Deputy Director..... O-12 OD II: Center to Reduce Cancer Health Disparities..... O-12 OD III: Office of the Deputy Director for Extramural Science..... O-13 OD IV: Office of Communications ..... O-14 OD IV: Office of Science Planning and Assessment..... O-14 OD IV: Office of Budget and Financial Management ..... O-14 Division of Basic Sciences ..... O-15 Division of Clinical Sciences ..... O-16 Division of Cancer Epidemiology and Genetics..... O-17 Division of Cancer Prevention..... O-18 Division of Cancer Control and Population Sciences ..... O-19 Division of Cancer Treatment and Diagnosis..... O-20 Division of Cancer Biology ..... O-21 Division of Extramural Activities ..... O-22	
<b>Cancer Statistics</b>	Number of Deaths for the Five Leading Cancer Sites..... C-1 Relationship of Cancer to the Leading Causes of Death in the U.S. .... C-1 Estimated New Cancer Cases and Deaths ..... C-2 The Cost of Cancer ..... C-3 Average Years of Life Lost Per Person Dying of Cancer..... C-4 Five-Year Relative Survival Rates by Cancer Site..... C-5 Cancer Mortality Rates, Changes from 1973 to 1997: Ages Under 65 ..... C-6 Ages Over 65..... C-7 Cancer Mortality Rates by Race ..... C-8 Cancer Incidence Rates by Race..... C-9 The Prevalence of Cancer..... C-10	
<b>Budget Data</b>	NCI Budget ..... B-1 Program Structure ..... B-2 Extramural Funds ..... B-3 NCI Obligations by Mechanism..... B-4 Division Obligations by Mechanism..... B-5 NIH Management Fund Reimbursement ..... B-6 Special Sources of Funds ..... B-7 Research Funding for Various Research Areas ..... B-8	

<b>Extramural Programs</b>	Research Project Grants:	
	Number of Awards .....	E-1
	Requested, Awarded.....	E-2
	Awards by Activity Code.....	E-3
	Activity Code Descriptions .....	E-4
	Cancer Centers	
	By State.....	E-5
	Specialized Programs of Research Excellence (SPORE).....	E-6
	National Research Service Awards – Pre and Post Doctoral Trainees ....	E-7
	Construction/Renovation Funding.....	E-8
	Grant and Contract Awards by State .....	E-9
Grant and Contract Awards by Country.....	E-10	
Institutions Receiving More than \$15,000,000 in NCI Support .....	E-11	
<b>Historical Trends</b>	Appropriations of the NCI.....	H-1
	Bypass Budget Requests .....	H-2
	Comparison of Bypass Requests and Appropriations of the NCI.....	H-3
	Comparison of Dollars, Positions and Space.....	H-4
	Personnel Resources .....	H-5

This publication may be viewed on the World Wide Web by pointing a browser to the Financial Management Branch homepage on the National Cancer Institutes website: [www.nci.nih.gov](http://www.nci.nih.gov) or [www.cancer.gov](http://www.cancer.gov) .

## Executive Summary

---

### Fiscal Year 2000 Annual Report\*

#### BUDGET IN REVIEW

This report provides a summary of the distribution of the FY 2000 budget among the various National Cancer Institute (NCI) research programs and funding mechanisms, funding policies influencing grant awards, and comparisons with prior year allocations. Additional information on the NCI budget is accessible from the NCI Home Page (<http://www.nci.nih.gov/>).

#### Summary

Funds available to the NCI in fiscal year 2000 totaled over \$3.311 billion, reflecting an increase of 15% and \$420 million over the previous fiscal year. This increase represented the largest single year dollar expansion in the NCI's 63 year existence. Thus, the NCI research community was able to initiate many of the research opportunities and challenges presented in the annual NCI Budget Proposal: *The Nation's Investment in Cancer Research*.

Fiscal highlights from FY 2000 include:

- Of the \$420 million increase, over 54% --\$225 million -- was allocated for Research Grants
- The greatest number of Research Project Grants (RPG)-- 4,526 -- in NCI's history were funded
- Nearly 1/3<sup>rd</sup> of the total NCI budget supported ongoing non-competing (Type 5) RPGs
- Over 1/4<sup>th</sup> of the RPGs awarded were new (Type 1) or competing renewal (Type 2) awards
- RO1 grants were funded to the 22<sup>nd</sup> percentile
- Over 300 grants and \$67 million were funded as Small Business Innovation Research awards
- \$83 million or 20% of the FY 2000 increase was allocated for Cancer Prevention & Control
- The percent of the budget that Intramural Research represented dropped to 15.3%, down from 18% in 1996
- Staff and funds that supported the research contract effort located at the NCI at Frederick were transferred into the NCI Intramural Research program
- Research Career training activities (K awards) expanded by 1/3<sup>rd</sup>

---

\* This Executive Summary was presented on December 5, 2000 to the National Cancer Advisory Board (NCAB) of National Cancer Institute (NCI) in response to their request for an annual budget report and is designed to be an extract of the major financial events in 2000. Further details of these events are given in the remaining sections of this Fact Book.

## Distribution of the Budget by Funding Mechanism for FY 1999 and 2000

### Summary Points

Of the \$420 million increase:

- \$225 million, representing 54% of the increase was allocated for the Research Grants budget mechanism; an additional \$83 million (20%) was funded through the Cancer Prevention & Control budget mechanism
- Over \$157 million or 1/3<sup>rd</sup> of the increase was provided to the Research Project Grant (RPG) category, excluding Small Business Innovation Research awards
- Within the RPG category, nearly \$114 million of the increase was allocated to cover increased expenses for non-competing grants
- 4,526 RPGs, of which 306 were Small Business Innovation Research awards, were supported
- Funds for training and career development of current and future research scientists funded through Research Career Awards grew by over 33%
- Staff and funds that supported the contract located at the NCI at Frederick were transferred into the NCI Intramural Research program in FY 2000

### NCI Dollars by Mechanism for FY 1999 and 2000

(in thousands)

	1999	2000*	Change '99-00	
			Am't	%
Research Project Grants:				
Noncompeting	\$936,030	\$1,050,107	\$114,077	12%
Admin Supplements	22,831	23,721	890	4%
Competing	344,995	387,083	42,088	12%
Subtotal RPG	1,303,856	1,460,911	157,055	12%
Small Business Innovation Research	57,917	67,090	9,173	16%
Total RPG	1,361,773	1,528,001	166,228	12%
Cancer Centers	153,157	169,068	15,911	10%
SPOREs	42,564	52,282	9,718	23%
Total, Centers & SPOREs	195,721	221,350	25,629	13%
Research Career Program	30,802	40,869	10,067	33%
Cancer Education	16,761	16,821	60	0%
Clinical Cooperative Groups	120,175	144,608	24,433	20%
Other Grants	31,869	30,378	-1,491	-5%
Subtotal, Other	199,607	232,676	33,069	17%
Total, Research Grants	1,757,101	1,982,027	224,926	13%
National Research Service Awards	57,168	56,179	-989	-2%
R&D Contracts	214,133	251,579	37,446	17%
Intramural Research	448,226	507,785	59,559	13%
Research Management & Support	105,600	120,586	14,986	14%
Cancer Prevention & Control	306,342	389,425	83,083	27%
Construction	3,000	3,500	500	17%
<b>Total NCI</b>	<b>2,891,570</b>	<b>3,311,081</b>	<b>419,511</b>	<b>15%</b>
AIDS research included above	[239,190]	[244,623]	[5,433]	2%

**Note:** Staff and funds that supported the research contract effort located at the NCI at Frederick were transferred into the NCI Intramural Research program in FY2000

\* Does not include \$3.5 million received by the NCI from the US Postal Service's sale of the Breast Cancer Stamp

## Percent Share of Total NCI Dollars

### *Summary Points*

- Cancer Prevention and Control's part of the budget has increased from 9.6% to 11.8%
- Intramural Research's share has declined from 18.0% to 15.3%
- Other mechanisms show slight shifts in their percentage share
- To move a percentage point in FY 2000 would have required a redirection of approximately \$33 million

	<b>1996</b>	<b>1997</b>	<b>1998</b>	<b>1999</b>	<b>2000</b>
Research Project Grants	45.9%	47.0%	48.7%	47.1%	46.1%
Cancer Centers	6.1%	5.5%	5.3%	5.3%	5.1%
SPOREs	1.1%	1.2%	1.2%	1.5%	1.6%
Clinical Cooperative Groups	4.0%	3.7%	3.7%	4.2%	4.4%
Intramural Research	18.0%	17.3%	17.3%	15.5%	15.3%
R&D Contracts	7.4%	7.7%	6.8%	7.4%	7.6%
Cancer Prevention & Control	9.6%	9.7%	9.9%	10.6%	11.8%

## Funding Trends

(in millions)

### *Summary Points*

- The NCI budget has increased by almost \$1.1 billion or 47% from FY1996
- Funds for Research Project Grants have increased 48%, the same rate as the total NCI budget
- SPOREs, Clinical Cooperative Groups, Cancer Prevention & Control, and R&D Contracts have experienced percentage increases greater than the total NCI growth
- Intramural Research and Centers have expanded at a smaller percentage than the total NCI growth

	<b>1996</b>	<b>1997</b>	<b>1998</b>	<b>1999</b>	<b>2000</b>
Total NCI	\$2,254.9	\$2,389.1	\$2,527.5	\$2,891.6	\$3,311.1
Research Project Grants	1,034.5	1,123.3	1,230.8	1,361.8	1,528.0
Intramural Research	406.9	412.5	437.8	448.2	507.8
Cancer Centers	138.4	131.9	134.0	153.2	169.1
SPOREs	24.7	28.8	30.9	42.6	52.3
Clinical Cooperative Groups	89.2	88.5	93.0	120.2	144.6
Cancer Prevention & Control	216.2	231.9	249.9	306.3	389.4
R&D Contracts	166.3	184.3	171.1	214.1	251.6

<b>% Growth by Mechanism</b>	<b>1996 to 1997</b>	<b>1997 to 1998</b>	<b>1998 to 1999</b>	<b>1999 to 2000</b>	<b>1996 to 2000</b>
Total NCI	6%	6%	14%	15%	47%
Research Project Grants	9%	10%	11%	12%	48%
Intramural Research	1%	6%	2%	13%	25%
Cancer Centers	-5%	2%	14%	10%	22%
SPOREs	17%	7%	38%	23%	112%
Clinical Cooperative Groups	-1%	5%	29%	20%	62%
Cancer Prevention & Control	7%	8%	23%	27%	80%
R&D Contracts	11%	-7%	25%	17%	51%



## Research Project Grants

(in thousands)

### Summary Points

- 90% of competing dollars supported grants awarded within the established payline; 10% supported grants as an exception to the payline
- RFA funds remained at the FY 1999 dollar level and were 6% of FY 2000 competing dollars
- Monies used to fund exception grants decreased in FY 2000, to 11% of competing funds compared with 18% in FY 1999
- On average grants were reduced 11-12% below recommended levels
- Funds -- \$15 million -- for Accelerated Executive Review permitted the award of 53 grants
- Research applications submitted to NCI increased by approximately 4%

	1999		2000*	
	No.	Amount	No.	Amount
Total RPGs	4,351	\$1,361,773	4,526	\$1,528,001
Small Business Innovation Research	291	57,917	306	67,090
RPGs, less SBIR Program	4,060	1,303,856	4,220	1,460,911
Continuation or non-competing grants funded	2,816	930,346	3,101	1,040,265
Competing grants funded	1,244	344,995	1,119	387,083
Administrative supplements		22,831		23,721
Partial assessment for DHHS Program Evaluation		5,684		9,842
Funds set aside within competing dollars for:				
Grants within paylines:	1,057	283,454	986	345,621
Traditional R01	746	189,770	724	216,671
Program projects (P01)	28	38,461	39	73,307
RFA grants	71	24,176	56	24,450
RFA's share of competing grant funds		7.0%		6.3%
Exception grants	187	61,541	132	41,462
Exception grants share of competing grant funds		18%		11%
Competing application requests	3,878		4,026	
Funding Success Rate	32%		28%	
Percentile funding for R01 grants (R01)	24th		22 <sup>nd</sup>	
Average cost for competing grants		\$277		\$346
Average reduction below recommended levels		-11%		-10% **

\* Does not include \$3.5 million received by the NCI from the US Postal Service's sale of the Breast Cancer Stamp

\*\* P01 round 2 and P01 round 3 average reduction from recommended levels was -15%.

## Research Career Awards – “K” Program

(in thousands)

### Summary Points

- The Research Career Award mechanism had a 33% growth in FY2000
- K08 Clinical Investigator award, K23 Mentored Patient Oriented and K24 Mid-Career Patient Oriented Awards received funding emphasis
- The National Heart, Lung, and Blood Institute is administering the K30 Institutional Curriculum Awards; NCI’s effort in FY 2000 was \$1.6 million

	1999		2000	
	No.	Amount	No.	Amount
K01 Temin Awards	25	\$2,809	21	\$2,660
K01 Minority Mentored Career Development Award	16	2,144	37	4,729
Subtotal K01s	41	4,953	58	7,389
K04 Research Career Development (phasing out)	6	414	2	127
K07 Preventive Oncology	38	3,618	44	4,469
K08 Clinical Investigator	121	11,461	133	14,402
K11 Physician Investigator (phasing out)	9	823	2	181
K12 Institutional Clinical Oncology Research	20	6,833	21	7,671
K22 Transition Career Development	0	0	4	560
K23 Patient-Oriented Career	10	1,310	23	2,964
K24 Patient-Oriented Career --Mid Career	13	1,390	29	3,108
Subtotal Research Career Program	258	30,802	316	40,871
K30 Institutional Curriculum Awards- Administered by NHLBI	4	800	8	1,600
Total Research Career Program	262	31,602	324	42,471

## Research Dollars by Various Cancers

(in millions)

### Summary Points

- Funding listed below for various cancers may overlap
- Funding for cancers listed below do not represent the entire NCI budget

	<b>1996</b>	<b>1997</b>	<b>1998</b>	<b>1999</b>	<b>2000</b>
Total NCI Budget	\$2,254.9	\$2,389.1	\$2,551.3	\$2,891.0	\$3,311.1
Brain & Central Nervous System Cancers	41.6	46.1	54.3	63.5	71.9
Breast Cancer	317.5	332.0	348.7	387.2	438.7
Cervical Cancer	51.6	55.8	58.0	66.3	67.0
Colorectal Cancer	98.0	103.2	121.0	152.9	175.8
Head and Neck Cancers	34.3	38.5	41.9	45.9	47.0
Hodgkin's Disease	8.0	8.1	8.3	8.2	9.4
Leukemia	79.3	91.2	103.4	122.2	141.7
Liver Cancer	31.4	35.3	38.1	39.8	46.2
Lung Cancer	119.4	132.4	139.8	151.0	175.0
Melanoma	36.0	43.3	50.3	60.1	67.9
Non Hodgkin's Lymphoma	49.9	52.7	57.1	66.2	70.4
Ovarian Cancer	36.5	41.7	40.8	56.5	65.5
Pancreatic Cancer	8.1	10.2	14.2	17.3	20.0
Prostate Cancer	71.7	82.3	86.9	135.7	203.2
Stomach Cancer	7.6	9.3	8.2	7.6	8.2
Uterine Cancer	8.1	8.1	12.2	13.8	16.0

# National Cancer Institute

---

## **Director=s Biography**

### **Richard D. Klausner, M.D.**

Dr. Klausner was appointed as the Director of the National Cancer Institute (NCI) on August 1, 1995. From 1984 until 1997 he was Chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health & Human Development. Dr. Klausner received his undergraduate degree from Yale University and his medical degree from Duke University. After post-graduate medical training at Harvard, he began his research career at the National Institutes of Health in 1979.

Dr. Klausner is well known for his contributions to multiple aspects of cell and molecular biology. Over the past several years, he has been recognized as one of the 20 most highly cited scientists in the world in this burgeoning area of biology and biomedical research. Dr. Klausner=s research has illuminated the genetics and biochemistry of metals as essential but toxic nutrients for virtually all forms of life, has illuminated the pathways by which molecules traffic and speak to each other within the cell, and has described novel mechanisms by which tumor suppressor genes function.

His work has been recognized with numerous honors and awards including the Dickson Prize and the William Damashek Prize for Major Discoveries in Hematology. In 1993, Dr. Klausner was elected to the National Academy of Sciences and chaired their project charged with writing standards for science education for the United States from kindergarten through 12<sup>th</sup> grade. This project represents the first comprehensive attempt to describe a vision of scientific literacy for all students and to provide the criteria for the educational system required to achieve the fulfillment of that vision.

Dr. Klausner is the past President of the American Society for Clinical Investigation. In October 1996, he was elected to the Institute of Medicine. He is the author of over 300 scientific articles and several books.

## Former Directors of the National Cancer Institute

---

**Samuel Broder, M.D.**

December 1988-March 1995

Dr. Broder joined NCI in 1972 as a Clinical Associate in the Metabolism Branch. In 1981, he became Associate Director for NCI's Clinical Oncology Program. In 1985 he led the laboratory team that discovered the therapeutic effects of AZT and other drugs now approved for the treatment of AIDS including DDI and DDC.

**Vincent T. DeVita, Jr., M.D.**

January 1980 - June 1980 (Acting)

July 1980 - August 1988

Dr. DeVita joined NCI in 1963 as a Clinical Associate in the Laboratory of Chemical Pharmacology. He served NCI as head of the Solid Tumor Service, Chief of the Medicine Branch, Director of the Division of Cancer Treatment and Clinical Director prior to his appointment as Director of NCI.

**Arthur Canfield Upton, M.D.**

July 1977 - December 1979

Prior to his tenure as NCI Director, Dr. Upton served as Dean of the School of Basic Health Sciences at the State University of New York at Stony Brook.

**Frank Joseph Rauscher, Jr., Ph.D.**

May 1972 - October 1976

Dr. Rauscher served as Scientific Director for Etiology, NCI, prior to his appointment as Director of NCI in 1972.

**Carl Gwin Baker, M.D.**

November 1969 - July 1970 (Acting)

July 1970 - April 1972

During his tenure with PHS, Dr. Baker served as Scientific Director for Etiology, NCI, and as Acting Director of NCI prior to his appointment as Director in July 1970.

**Kenneth Milo Endicott, M.D.**

July 1960 - November 1969

Dr. Endicott served as Chief of the Cancer Chemotherapy National Service Center, PHS, and as Associate Director, NIH, prior to being appointed Director, NCI in July 1960.

**John Roderick Heller, M.D.**

May 1948 - June 1960

Dr. Heller joined PHS in 1934 and became Chief of the Venereal Disease Division prior to his appointment as Director of NCI in 1948.

**Leonard Andrew Scheele, M.D.**

July 1947 - April 1948

Dr. Scheele served in various capacities during his tenure with PHS prior to his appointment as Assistant Chief and, subsequently, Director of NCI in July 1947.

**Roscoe Roy Spencer, M.D.**

August 1943 - July 1947

Dr. Spencer became NCI's first Assistant Chief and, subsequently, was appointed Director of the Institute in 1943.

**Carl Voegtlin, Ph.D.**

January 1938 - July 1943

Dr. Voegtlin served as Professor of Pharmacology and Chief of the Division of Pharmacy at the Hygienic Laboratory prior to becoming the first Director of NCI in 1938.

# National Cancer Advisory Board

## Membership and Term

---

- 2002 **Chairperson**  
**Phillip A. Sharp, Ph.D.**  
Center for Cancer Research  
Massachusetts Institute of Technology  
Cambridge, Massachusetts 02139
- 2006 Samir Abu-Ghazaleh, M.D.  
Avera Cancer Institute  
Sioux Falls, South Dakota 57105
- 2006 James O. Armitage, M.D.  
College of Medicine  
University of Nebraska Medical Center  
Omaha, Nebraska 68198-6545
- 2006 Ralph S. Freedman, M.B.B.Ch., Ph.D.  
Department of Gynecologic Oncology  
The University of Texas  
Houston, Texas 77030
- 2006 James H. French, M.D.  
The Center for Plastic Surgery  
Annandale, Virginia 22003
- 2006 Arthur W. Nienhuis, M.D.  
St. Jude Children's Research Hospital  
Memphis, Tennessee 38105
- 2004 Mr. Stephen C. Duffy  
American Academy of Facial Plastic  
& Reconstructive Surg. & International  
Federation of Facial Plastic Surg. Society  
Alexandria, Virginia 22314
- 2004 Elmer E. Huerta, M.D., M.P.H.  
Cancer Risk Assess. & Screening Ctr.  
Washington Hospital Center  
Washington, DC 20010
- 2004 Susan M. Love, M.D.  
Department of Surgery  
School of Medicine  
University of California  
Pacific Palisades, California 90272
- 2004 The Honorable James E. McGreevey  
Mayor, Woodbridge Township  
Woodbridge, New Jersey 07095
- 2004 Larry Norton, M.D.  
Medical Breast Oncology  
Evelyn H. Lauder Breast Center  
Memorial Sloan-Kettering Cancer Center  
New York, New York 10021
- 2004 Amelie G. Ramirez, Dr. P. H  
Department of Medicine  
Chronic Disease Prevention  
& Control Research Center  
Baylor College of Medicine  
San Antonio, TX 78230
- 2002 Richard J. Boxer, M.D.  
Medical College of Wisconsin  
Urology Specialists S.C.  
Milwaukee, WI 53209
- 2002 Frederick P. Li, M.D.  
Division of Cancer Epidemiology & Control  
Dana-Farber Cancer Institute - Smith 201  
Boston, MA 02115
- 2002 Sandra Millon-Underwood, Ph.D., R.N.  
University of Wisconsin  
-Milwaukee School of Nursing  
Milwaukee, WI 53211
- 2002 Ivor Royston, M.D.  
Sidney Kimmel Cancer Center  
San Diego, California 92121
- 2002 Ms. Ellen L. Stovall  
National Coalition for Cancer Survivorship  
Silver Spring, MD 20910
- Executive Secretary  
Marvin R. Kalt, Ph.D.
- Committee Management Officer  
Ms. Linda Quick-Cameron

**National Cancer Advisory Board (Continued)**

---

**Ex Officio Members**

Ms. Ann Brown  
Chairman  
Consumer Product Safety Commission  
Bethesda, Maryland 20842

Ms. Carole M. Browner  
Administrator  
Environmental Protection Agency  
Washington D.C. 20460

The Honorable J. Jarrett Clinton, M.D., M.P.H.  
Acting Assistant to the Assistant Secretary of Defense  
for Health Affairs  
Pentagon  
Washington, D.C. 20301-1200

Jane E. Henney, M.D.  
Commissioner  
Food and Drug Administration  
Rockville, Maryland 20857

The Honorable Alexis M. Herman  
Secretary of Labor  
Washington D.C. 20210

Ruth Kirschstein, M.D.  
Principal Deputy Director  
National Institute of Health, PHS  
Bethesda, Maryland 20892

Kenneth W. Kizer, M.D., M.P.H.  
Under Secretary for Health  
Veterans' Health Administration  
Department of Veterans' Affairs  
Washington, D.C. 20420

Ms. Rachel Levinson  
Assistant Director for Life Sciences  
Office of Science and Technology Policy  
The White House  
Washington, D.C. 20506

Kenneth Olden, Ph. D.  
Director  
National Institute of Environmental  
Health Sciences  
National Institute of Health  
Research Triangle Park, NC 27709

Ari Patrinos, Ph. D.  
Deputy Director, Office of Biological  
and Environmental Research  
Office of Energy Research  
U.S. Department of Energy  
Washington, D.C. 20585

Linda Rosenstock, M.D., M.P.H.  
Director  
National Institute for Occupational  
Safety and Health  
Washington, D.C. 20201-0001

The Honorable Donna E. Shalala, Ph.D.  
Secretary  
Department of Health and Human Services  
Washington, D.C. 20201

**Alternates to Ex Officio Members**

Steven K. Akiyama, Ph.D.  
Associate Director for Research and Training  
Division of Intramural Research  
National Institute of Environmental Health Sciences  
National Institute of Health  
Research Triangle Park, NC 27709  
**(Kenneth Olden, Ph.D. - NIEHS)**

Michael A. Babich, Ph.D.  
Directorate for Health Science  
U.S. Consumer Product Safety Commission  
Bethesda, Maryland 20814  
**(Ms. Ann Brown U.S. CPSC)**

Peter Kirchner, Ph.D.  
Program Manager  
Office of Biological & Environmental Research  
Division of Medical Science  
U.S. Department of Energy  
Germantown, MD 20874-1290  
**(Ari Patrinos, Ph.D. - DOE)**

Alison Martin, M.D.  
Division of Oncology FDA  
Food and Drug Administration  
Rockville, Maryland 20857  
**(Jane E. Henney, M. D. - FDA)**

Hugh W. McKinnon, M.D., M.P.H.  
Associate Director for Health  
National Risk Management Research  
Laboratory (MD-225)  
U.S. Environmental Protection Agency  
Cincinnati, Ohio 45268  
**(Ms. Carole M. Browner - EPA)**

T. G. Patel, M.D., M.A.C.P.  
Captain MC USN (Retired)  
Program Chief  
Veterans Health Administration  
Department of Veterans Affairs  
Washington, DC 20420  
**(Kenneth W. Kizer, M.D. - VA)**

Eugene Schwartz, M.D.  
Medical Officer  
Office of Occupational Medicine  
Department of Labor, OSHA  
Washington, D. C. 20210  
**(The Honorable Alexis M. Herman - DOL)**



**NCAB SUBCOMMITTEE ASSIGNMENTS**

**Subcommittee on Activities and Agenda**

Dr. Phillip Sharp - Chair  
Dr. Frederick P. Li  
Dr. Susan M. Love  
Dr. Arthur W. Neinhuis  
Dr. Larry Norton  
Ms. Ellen Stovall  
EXECUTIVE SECRETARY: Dr. Marvin Kalt  
(301) 496-5147

**Subcommittee on Cancer Centers**

Dr. Arthur W. Nienhuis - Chair  
Dr. James O. Armitage  
Dr. Richard J. Boxer  
Dr. Ralph S. Freedman  
Dr. Elmer E. Huerta  
Dr. Larry Norton  
Dr. Kenneth Olden (NIEHS, Ex Officio)  
Dr. Amelie G. Ramirez  
Dr. Phillip A. Sharp (Ex Officio)  
EXECUTIVE SECRETARY: Dr. Brain Kimes  
(301) 496-8537

**Subcommittee on Clinical Investigation**

Dr. Larry Norton - Chair  
Dr. Samir Abu-Ghazaleh  
Dr. James O. Armitage  
Dr. Richard J. Boxer  
Dr. Ralph S. Freedman  
Dr. James H. French  
Dr. Elmer E. Huerta  
Dr. Susan M. Love  
Dr. Alison Martin (FDA, Ex Officio)  
Dr. Ivor Royston  
Ms. Ellen Stovall  
ACTG. EXECUTIVE SECRETARY: Dr. Ellen Feigal  
(301) 496-2522

**Subcommittee on Special Actions**

Dr. Frederick Li - Chair  
Committee of the Whole  
Dr. Phillip A. Sharp (Ex Officio)  
EXECUTIVE SECRETARY: Dr. Marvin Kalt  
(301) 496-5147

**Subcommittee on Planning and Budget**

Ms. Ellen Stovall - Chair  
Mr. Stephen Duffy  
Hon. James E. McGreevey  
Dr. Sandra Millon-Underwood  
Dr. Arthur W. Nienhuis  
Dr. Amelie G. Ramirez  
Dr. Phillip A. Sharp (Ex Officio)  
EXECUTIVE SECRETARY: Ms. Cherie Nichols  
(301) 496-5515

**Ad Hoc Subcommittee on Confidentiality**

Dr. Frederick Li - Chair  
Dr. Samir Abu-Ghazaleh  
Mr. Stephen C. Duffy  
Dr. Ivor Royston  
Ms. Ellen Stovall  
EXECUTIVE SECRETARY: Ms. Mary McCabe  
(301) 496-6404

**Ad Hoc Subcommittee on Communications**

Dr. Susan M. Love - Chair  
Dr. Richard J. Boxer  
Mr. Steven C. Duffy  
Dr. James H. French  
Hon. James McGreevey  
Dr. Amelie G. Ramirez  
Ms. Ellen Stovall  
EXECUTIVE SECRETARY: Dr. Susan Sieber  
(301) 496-5946

**Ad Hoc Subcommittee on Coding for Research on Minorities**

Dr. Frederick Li - Chair  
Dr. Elmer Huerta  
Dr. Sandra Millon-Underwood  
Dr. Larry Norton  
Dr. Amelie G. Ramirez  
EXECUTIVE SECRETARY: Dr. Susan Sieber  
(301) 496-5946

## Board of Scientific Counselors Intramural Programs

---

### Subcommittee A: Clinical Sciences

Appointees	Expiration of Appointment	Appointees	Expiration of Appointment
Martin Abeloff, MD, Chair	2001		
Chi V Dang M.D., Ph.D.	2005	Margaret Tempero, M.D.	2004
Elizabeth Fontham, DPH	2005	Michael Cleary, M.D.	2003
Laurence Kolonel, M.D., Ph.D.	2005	Deborah Collyar, B.S.	2003
Richard O'Reilly, M.D.	2005	Timothy Eberlein, M.D.	2003
Alice Pentland, M.D.	2005	Elizabeth Holly, Ph.D.,	2003
Arthur Porter, M.D.	2005	Frank McCormick, Ph.D.	2003
Michael Thun, M.D.	2005	Beverly Mitchell, M.D.	2003
Carlos Arteaga, M.D.	2004	James Mule, Ph.D.	2003
Martin Cheever, M.D.	2004	Theodore Colton, SCD	2001
David Hunter, SCD	2004	Mark Israel, M.D.	2001
Michael Kastan, M.D.	2004	Timothy Kinsella, M.D.	2001
Olufunmilayo Olopade, MBBS	2004	John Mendelsohn, M.D.	2001
David Savitz, Ph.D.	2004	John Potter, MBBS, Ph.D.	2001

Executive Secretary - Abby Sandler, Ph.D.

### Subcommittee B: Basic Sciences

Bruce Stillman, Ph.D., Chair	2001		
Frederick Alt, Ph.D.	2005	Suzanne Sandmeyer, Ph.D.	2003
Gideon Dreyfuss, Ph.D.	2005	Andrey Shaw, M.D.	2003
Richard Kolodner, Ph.D.	2005	Mario Capecchi, Ph.D.	2002
Brook Mossman, Ph.D.	2005	Stephen Goff, Ph.D.	2002
Dinshaw Patel, Ph.D.	2005	Beatrice Hahn, M.D.	2002
Eileen White, Ph.D.	2005	Inder Verma, Ph.D.	2002
Jon Clardy, Ph.D.	2004	Max Cooper, M.D.	2001
David Housman, Ph.D.	2004	Naomi Rosenberg, Ph.D.	2001
Thomas Kelly, Ph.D., M.D.	2004	Anna Marie Skalka, Ph.D.	2001
Gregory L. Verdine, Ph.D.	2004	Craig Thompson, M.D.	2001
E. Peter Geiduschek, Ph.D.	2003	Robert Tjian, Ph.D.	2001

Executive Secretary - Florence Farber, Ph.D.

---

## Board of Scientific Advisors Extramural Programs

---

Frederick R. Applebaum, M.D. Chair	2004		
David B. Abrams, Ph.D.	2004	Herbert Y. Kressel, M.D.	2002
David S. Alberts, M.D.	2004	Amy S. Langer, M.B.A.	2002
Hoda Anton-Culver, Ph.D.	2004	Franklyn G. Prendergast, M.D., Ph.D.	2002
Esther H. Chang, Ph.D.	2004	Joseph V. Simone, M.D.	2002
Mary Beryl Daly, M.D., Ph.D.	2004	Louise C. Strong, M.D.	2002
W. Gillies McKenna, M.D., Ph.D.	2004	Daniel D. Von Hoff, M.D., F.A.C.P.	2002
Susan B. Horwitz, Ph.D.	2004	Barbara L. Weber, M.D.	2002
Kenneth W. Kinzler, Ph.D.	2004	Alice S. Whittemore, Ph.D.	2002
Richard L. Schilsky, M.D.	2004	Elias A. Zerhouni, M.D.	2002
William C. Wood, M.D.	2004	Caryn E. Lerman, Ph.D.	2001
Ellen V. Sigal, Ph.D.	2003	Enrico Mihich, M.D.	2001
Virginia L. Ernster, Ph.D.	2002	John D. Minna, M.D.	2001
Suzanne W. Fletcher, M.D.	2002	Nancy E. Mueller, Sc.D.	2001
Waun Ki Hong, M.D.	2002	Peter K. Vogt, Ph.D.	2001
Tyler E. Jacks, Ph.D.	2002	Robert C. Young, M.D.	2001

Executive Secretary - Paulette S. Gray, Ph.D.

## President's Cancer Panel

---

**Harold Freeman, M.D.**      **2000**

Chairman  
Director and CEO  
North General Hospital  
New York, NY

**Frances M. Visco, Esq.**      **2000**

President  
National Breast Cancer Coalition  
Washington, DC

**Paul Calabresi, M.D.**      **2000**

Professor and Chairman, Emeritus  
Department of Medicine  
Brown-Tufts Cancer Center  
Rhode Island Hospital  
New England Medical Center  
Providence, RI

**Maureen O. Wilson, Ph.D.**

Executive Secretary

---

## Executive Committee Members

---

**Richard Klausner, M.D.**

Director

**Alan Rabson, M.D.**

Deputy Director

**Carl J. Barrett, Ph. D.**

Director, Division of Basic Sciences

**Joseph Fraumeni, M.D.**

Director, Division of Cancer Epidemiology and  
Genetics

**Harold P. Freeman, M.D.**

Director, Center to Reduce Cancer Health Disparities

**Peter Greenwald, M.D.**

Director, Division of Cancer Prevention

**MaryAnn Guerra**

Deputy Director for Management

**Joe Harford, Ph.D.**

Associate Director for Special Projects

**Marvin Kalt, Ph.D.**

Director, Division of Extramural Activities

**Edison Liu, M.D.**

Director, Division of Clinical Science

**Barbara Rimer, Dr. P.H.**

Director, Division of Cancer Control and Population  
Sciences

**Susan Sieber, Ph.D.**

Deputy Director for Communications

**Dinah Singer, Ph.D.**

Director, Division of Cancer Biology


**Robert Wittes, M.D.**


Director, Division of Cancer Treatment and Diagnosis  
Deputy Director for Extramural Science

**Sandy Koeneman, M.S., M.P.A.**

Executive Secretary

# National Cancer Institute





# Office of Management

Director  
Ms. MaryAnn Guerra  
301-435-2455

**Office of Space and Facilities Planning**  
Chief  
Mr. Frank Battistello  
301-496-1724

## Information Systems and Computer Services

Associate Director  
Dr. Jed Rifkin  
301-496-1629

Infrastructure Services  
Chief  
Mr. Todd Cox  
301-496-1629

Customer Resource Services  
Chief  
Mr. Calvin Hollinsworth  
301-496-1038

Web Development Services  
Chief  
Mr. Dan Sands  
301-496-1629

Business System Services  
Chief  
Mr. Harvey Karch  
301-496-1629

## Administrative Operations

Associate Director  
Ms. Janis Mullaney  
301-435-7520

Human Resources Management  
and Consulting Branch  
Chief  
Mr. Dan DuPuis  
301-497-3337

### Administrative Resource Centers (ARC)

Division of Basic Sciences  
Manager  
Ms. Betty Fitzpatrick  
301-496-5372

Division of Clinical Sciences  
Manager  
Mr. Bob Barber  
301-402-2559

Division of Cancer  
Epidemiology and Genetics  
Manager  
Ms. Donna Gellerson  
301-594-7507

Division of Cancer Treatment  
and Diagnosis  
Manager  
Mr. Joseph Jenkins  
301-594-5965

Division of Cancer Biology  
Manager  
Ms. Bridgette Tobiasen  
301-496-2871

Frederick Cancer Research  
and Development Center  
Manager  
Ms. Gretchen Jolles  
301-846-1166

Division of Cancer Control and  
Population Sciences  
Ms. Ellen Moul (Manager)  
301-496-8571

Division of Cancer Prevention  
Manager  
Ms. Jackie Havens  
301-496-9606

Office of the Director  
Manager  
Ms. Susan Kiser  
301-496-5801

DEA/6116 ARC  
Manager  
Ms. Lisa Mascone  
301-594-3343

ARC 10A  
Acting Manager  
Ms. Sharon Desmond  
301-496-6303

EP ARC  
Manager  
Mr. Phil Lowery  
301-402-5516

## Innovation & Evaluation

Associate Director  
Ms. Pat Abell  
301-402-3511

Management Analysis Branch  
Chief  
Ms. Marilyn Jackson  
301-496-6985

Strategic Technical Review &  
Innovative Initiatives Core  
Ms. Cathleen Peters (Chief)  
301-496-2720

ARC 10B  
Manager  
Mr. Gary Unger  
301-496-6303

ARC 37  
Manager  
Mr. Todd Danielson  
301-496-4967

ARC 41  
Manager  
Ms. Kathy McBrien  
301-496-3667

NCICB  
Manager  
Mr. Patrick Miller  
301-435-2509

## Business Operations and Development



Acting Associate Director  
Mr. Jack Campbell  
301-496-8628


Technology Development and  
Commercialization Branch  
Chief  
Dr. Kathy Sybert  
301-496-0477

Grants Administration Branch  
Chief  
Mr. Leo Buscher Jr.  
301-496-7753

Research Contracts and  
Acquisition Branch  
Chief  
Mr. Jack Campbell  
301-496-8628

Frederick-Management  
Operations & Support Branch  
Chief  
Mr. Ron Defelice  
301-846-1113







**Office of Communications**  
Director  
Dr. Susan Sieber  
301-496-5946

**Cancer Information Products and Systems**  
Associate Director  
Dr. Ann Thum  
301-496-9096

**Outreach and Partnerships**  
Associate Director  
Ms. Elisabeth Handley  
301-402-5575

**Media and Public Communications**  
Acting Associate Director  
Mr. Jim Mathews  
301-496-6631

**Communications Coordination**  
Associate Director  
Ms. Nelvis Castro  
301-594-5114

**Technologies and Services**  
Associate Director  
Mr. Michael Moore  
301-594-3331

**Office of Science Planning and Assessment**  
Director  
Ms. Cherie Nichols  
301-496-5515

**Office of Women's Health**  
Deputy  
Ms. Anna Levy  
301-435-3860

**Science Planning Branch**  
Chief  
Ms. Kathie Reed  
301-435-5163


**Program Assessment Branch**  
Chief  
Dr. James Corrigan  
301-496-5515


**Connections Team**  
Team Leader  
Mr. Bernard Glassman  
301-402-2187


**Office of Budget and Financial Management**  
Associate Director  
Mr. John Hartinger  
301-496-5803

**Financial Management Branch**  
Chief  
Ms. Mary Cushing  
301-496-5803

**Extramural Financial Data Branch**  
Chief  
Mr. Stephen Hazen  
301-496-7660







## Division of Cancer Prevention Office of the Director

Director  
Dr. Peter Greenwald 301-496-6616  
Acting Deputy Directors  
Dr. Leslie Ford & Dr. Carolyn Clifford  
301-496-9569  
Associate Director for Clinical Research  
Dr. Leslie Ford 301-496-0265

**Office of Preventive Oncology**  
Chief  
Dr. Douglass Weed  
301-496-8640

**Chemoprevention Agent  
Development Research Group**  
Acting Chief  
Dr. James Crowell  
301-496-8640

**Early Detection  
Research Group**  
Chief  
Dr. John Gohagan  
301-496-8544

**Nutritional Science  
Research Group**  
Chief  
Dr. John Milner  
301-496-8573

**Community Oncology and  
Prevention Trials Research  
Group**  
Chief  
Dr. Lori Minasian  
301-496-8541

**Biometry Research  
Group**  
Chief  
Dr. Phillip Prorok  
301-496-8556

**Basic Prevention Science  
Research Group**  
Acting Chief  
Dr. Peter Greenwald  
301-496-6616

**Cancer Biomarkers  
Research Group**  
Chief  
Dr. Sudhir Srivastava  
301-496-8544

**Breast & Gynecologic Cancer  
Research Group**  
Chief  
Dr. Karen Johnson  
301-496-8526

**Gastrointestinal & Other Cancer  
Research Group**  
Chief  
Dr. Ernest Hawk  
301-496-8563


**Prostate & Urologic Cancer  
Research Group**  
Acting Chief  
Dr. Carolyn Clifford  
301-496-8563

**Lung & Upper Aerodigestive  
Cancer Research Group**  
Acting Chief  
Dr. Eva Szabo  
301-496-8544

**Division of Cancer Control and  
Population Sciences  
Office of the Director**

Director, Dr. Barbara Rimer, 301-594-6776  
Deputy Director, Dr. Robert Hiatt, 301-594-7206  
Assistant Deputy Director for  
Research Dissemination and Diffusion,  
Dr. Jon F. Kerner, 301-594-7294


**Office of Cancer  
Survivorship**  
Chief  
Dr. Julia H. Rowland  
301-435-7206



# Division of Cancer Treatment and Diagnosis Office of the Director

Director  
Dr. Robert Wittes  
301-496-4291

Deputy Director  
Dr. Ellen Feigal  
301-496-4291



**Division of Cancer Biology  
Office of the Director**

Director  
Dr. Dinah S. Singer  
301-496-8636

Deputy Director  
Dr. John A. Sogn  
301-496-8636

**Biological Carcinogenesis Branch**  
Chief  
Dr. Jack Gruber  
301-496-9740

**Tumor Immunology and Metastasis Branch**  
Chief  
Dr. Suresh Mohla  
301-496-1878

**Chemical and Physical Carcinogenesis Branch**  
Chief  
Dr. David Longfellow  
301-496-5471

**DNA and Chromosome Aberrations**  
Chief  
Dr. Bruce Wachholz  
301-496-9326

**Cancer Immunology and Hematology Branch**  
Chief  
Dr. R.Allan Mufson  
301-496-7815

**Structural Biology and Molecular Application Branch**  
Chief  
Dr. Daniel Gallahan  
301-435-5226

**Cancer Cell Biology Branch**  
Chief  
Dr. Colette Freeman  
301-496-7028



**Division of Extramural Activities**  
Director, Dr. Marvin R. Kalt  
301-496-5147  
Deputy Director, Dr. Paulette S. Gray  
301-496-4218  
Assistant Director, Dr. Cedric W. Long  
301-496-9138

**Office of Extramural Applications**  
Associate Director  
Dr. Paulette S. Gray  
301-496-4218

**Office of Referral, Review and Program Coordination**  
Associate Director  
Dr. Robert D. Hammond  
301-435-5655

**Applied Information Systems Branch**  
Chief  
Mr. James W. Seach  
301-496-7047

**Research Analysis and Evaluation Branch**  
Chief  
Ms. Rosemary Cuddy  
301-594-1110

**Grants Review Branch**  
Chief  
Dr. Olivia T. Preble  
301-496-7929

**Special Review and Resources Branch**  
Chief  
Dr. Kirt J. Vener  
301-496-7174

**Program Coordination and Referral Branch**  
Chief  
Dr. Ray Bramhall  
301-594-1403

**Applications Development and Operations Section**  
Chief  
Mr. Gregory P. Fischetti  
301-594-1067

**Technical Operations Section**  
Chief  
Ms. Diane Ostrow  
301-594-1124

**Research Program Review Section**  
Chief  
Dr. Virginia Wray  
301-496-9236

**Information Management Section**  
Chief  
Mr. Amir Sahar-Khiz  
301-594-1331

**Research Documentation Section**  
Chief  
Ms. Brenda Underwood  
301-594-1119

**Research Resources Review Section**  
Chief  
Dr. David Maslow  
301-496-2330

**Inquiry and Reporting Section**  
Chief  
Ms. Marilyn Gaston  
301-594-1111

## Number of 1997 Deaths for the Five Leading Cancer Sites by Age Group and Sex

All Ages		Under 15		15-34		35-54		55-74		75+	
Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
Lung & Bronchus 91,227	Lung & Bronchus 61,922	Leukemia 299	Leukemia 233	Leukemia 585	Breast 530	Lung & Bronchus 8,563	Breast 9,588	Lung & Bronchus 51,420	Lung & Bronchus 32,541	Lung 31,158	Lung & Bronchus 23,457
Prostate 32,889	Breast 41,943	Brain & ONS 228	Brain & ONS 207	NHL 468	Leukemia 381	Colon & Rectum 2,788	Lung & Bronchus 5,810	Colon & Rectum 12,873	Breast 16,992	Prostate 22,349	Colon & Rectum 16,494
Colon & Rectum 28,075	Colon & Rectum 28,619	Endocrine 107	Endocrine 74	Brain & ONS 412	Cervix 303	NHL 2,013	Colon & Rectum 2,262	Prostate 10,132	Colon & Rectum 9,716	Colon & Rectum 12,207	Breast 14,833
Pancreas 13,470	Pancreas 14,205	NHL 47	Soft Tissue 52	Soft Tissue 204	Brain & ONS 254	Brain & ONS 1,700	Ovary 1,958	Pancreas 6,860	Ovary 6,087	Pancreas 4,966	Pancreas 7,607
NHL 12,286	Ovary 13,507	Soft Tissue 42	Bone & Joints 31	Colon & Rectum 189	NHL 194	Pancreas 1,606	Cervix Uteri 1,740	NHL 5,256	Pancreas 5,598	Leukemia 4,657	NHL 5,849

Source: National Center for Health Statistics (NCHS) public - use file for 1997 deaths.

NHL = Non Hodgkin's Lymphoma

ONS = Other Nervous System

## Relationship of Cancer to the Leading Causes of Death in the United States, 1997

Rank	Cause	Number of Deaths	Age Adjusted Rate*	Percent of Total Deaths
	<b>All Causes</b>	<b>2,313,844</b>	<b>652.0</b>	<b>100.0%</b>
1	Heart Disease	726,906	193.7	31.4%
2	CANCER	539,566	163.7	23.3%
3	Cerebrovascular Diseases	159,786	40.6	6.9%
4	Emphysema, Bronchitis & Asthma	109,022	30.5	4.7%
5	Accidents	95,544	31.4	4.1%
6	Pneumonia & Influenza	86,443	21.1	3.7%
7	Diabetes Mellitus	62,634	18.2	2.7%
8	Human Immunodeficiency Virus Infection	30,517	10.2	1.3%
9	Suicide and Self-Inflicted Injury	25,331	6.7	1.1%
10	Cirrhosis of the Liver	25,171	8.2	1.1%
11	Nephritis & Nephrosis	22,395	6.0	1.0%
12	Septicemia	19,798	7.3	0.9%
13	Homicide	16,724	4.7	0.7%
14	Atherosclerosis	16,510	5.0	0.7%
15	Aortic Aneurysm	16,056	3.7	0.7%
	Other and Ill-Defined	361,441	101.1	15.6%

Source: NCHS Public-use file for 1997 deaths.

\* Rate per 100,000 Population and age adjusted to 1970 US population

## Estimated New Cancer Cases and Deaths by Sex for All Races 2000

Primary Site	Estimated New Cases			Estimated Deaths		
	Total	Male	Female	Total	Male	Female
All Sites	1,220,100	619,700	600,400	563,100	291,100	272,000
Oral Cavity and Pharynx	30,200	20,200	10,000	7,800	5,100	2,700
Tongue	6,900	4,500	2,400	1,700	1,100	600
Mouth	10,900	6,500	4,400	2,300	1,300	1,000
Pharynx	8,200	5,900	2,300	2,100	1,500	600
Other Oral Cavity	4,200	3,300	900	1,700	1,200	500
Digestive System	226,600	117,600	109,000	129,800	69,300	60,500
Esophagus	12,300	9,200	3,100	12,100	9,200	2,900
Stomach	21,500	13,400	8,100	13,000	7,600	5,400
Small Intestine	4,700	2,300	2,400	1,200	600	600
Colon	93,800	43,400	50,400	47,700	23,100	24,600
Rectum	36,400	20,200	16,200	8,600	4,700	3,900
Anus, Anal Canal, & Anorectum	3,400	1,400	2,000	500	200	300
Liver and Intrahepatic Bile Duct	15,300	10,000	5,300	13,800	8,500	5,300
Gallbladder & Other Biliary	6,900	2,900	4,000	3,400	1,200	2,200
Pancreas	28,300	13,700	14,600	28,200	13,700	14,500
Other Digestive	4,000	1,100	2,900	1,300	500	800
Respiratory System	179,400	101,500	77,900	161,900	93,100	68,800
Larynx	10,100	8,100	2,000	3,900	3,100	800
Lung and Bronchus	164,100	89,500	74,600	156,900	89,300	67,600
Other Respiratory	5,200	3,900	1,300	1,100	700	400
Bones and Joints	2,500	1,500	1,000	1,400	800	600
Soft Tissues	8,100	4,300	3,800	4,600	2,200	2,400
Skin (excl. basal & squamous)	56,900	34,100	22,800	9,200	6,000	3,600
Melanomas Of Skin	47,700	27,300	20,400	7,300	4,800	2,900
Other non-epithelial skin	9,200	6,800	2,400	1,900	1,200	700
Breast	184,200	1,400	182,800	41,200	400	40,800
Genital Organs	265,900	188,400	77,500	59,000	32,500	26,500
Cervix Uteri	12,800		12,800	4,600		4,600
Endometrium (uterus)	36,100		36,100	6,500		6,500
Ovary	23,100		23,100	14,000		14,000
Vulva	3,400		3,400	800		800
Vagina and other genital organs, female	2,100		2,100	600		600
Prostate	180,400	180,400		31,900	31,900	
Testis	6,900	6,900		300	300	
Penis and other genital organs, male	1,100	1,100		300	300	
0	0					
Urinary System	86,700	58,600	28,100	24,600	15,700	8,900
Urinary Bladder	53,200	38,300	14,900	12,200	8,100	4,100
Kidney and Renal Pelvis	31,200	18,800	12,400	11,900	7,300	4,600
Ureter and other urinary organs	2,300	1,500	800	500	300	200
Eye and Orbit	2,200	1,200	1,000	200	100	100
Brain and Other Nervous System	16,500	9,500	7,000	13,000	7,100	5,900
Endocrine Glands	20,200	5,600	14,600	2,100	1,000	1,100
Thyroid	18,400	4,700	13,700	1,200	500	700
Other Endocrine	1,800	900	900	900	500	400
Lymphomas and Myelomas	62,300	35,900	26,400	27,500	14,400	13,100
Hodgkin's Disease	7,400	4,200	3,200	1,400	700	700
Non-Hodgkin's Lymphoma	54,900	31,700	23,200	26,100	13,700	12,400
Multiple Myeloma	13,600	7,300	6,300	11,200	5,800	5,400
Leukemias	30,800	16,900	13,900	21,700	12,100	9,600
Lymphocytic Leukemias	11,300	6,400	4,900	6,100	3,500	2,600
Myeloid Leukemias	14,100	7,400	6,700	9,400	5,200	4,200
Other Leukemias	5,400	3,100	2,300	6,200	3,400	2,800
All Other Sites	34,000	15,700	18,300	36,600	18,500	18,100

Source: Cancer Facts & Figures-2000, American Cancer Society (ACS), Atlanta, Georgia 2000.  
Excludes basal and squamous cell skin and in situ carcinomas except urinary bladder.  
Incidence projections are based on rates from the NCI SEER Program 1979-1996.

## The Cost of Cancer

---

The direct medical cost of cancer is derived from the national data on costs per treatment episode. This estimate does not include the cost of the productivity lost while individuals are away from work due to treatment or disability or the value of lost productivity due to premature death. Figures for the direct medical cost of cancer and expenditures for all personal health care for 1995 are as follows:


<b>(in Millions)</b>	
<b>All Costs</b>	<b>Direct Cost</b>
All Cancers*	\$ 41,200
All Health Care	\$878,464
Percent Relationship of Cancer to All Health	5%

---

\*Hodgson TA, Cohen AJ. 1999. Medical Expenditures for major diseases. Health Care Financing Review, 21:119-64.

**Average Years of Life Lost  
Per Person Dying of Cancer  
All Races, Both Sexes, 1997**

---




Number of Years of Life Lost  
source: NCHS public-use data and 1996 life table

# 5 Year Relative Survival Rates by Site

## White and Black Patients, Males and Females


### 1989 to 1996



Data From NCI SEER Program  
<http://www.seer.cancer.gov/>

# Cancer Mortality Rates Changes from 1973 to 1997


## Ages Under 65



source: NCHS public-use data and 1996 life table

# Cancer Mortality Rates Changes from 1973 to 1997

Ages Over 65



Percent Change, 1973-1997  
source: NCHS public-use data and 1996 life table



## Cancer Mortality Rates By Race United States, 1993-1997

---

Cancer Site	Mortality Rates per 100,000		Ratio
	Blacks	Whites	Blacks/Whites
All Sites	219.1	165.0	1.3
Males	299.6	203.8	1.5
Females	166.9	138.5	1.2
All Sites Except Lung & Bronchus	159.9	116.1	1.4
Males	202.9	135.9	1.5
Females	133.5	103.8	1.3
Lung and Bronchus	59.2	48.9	1.2
Males	96.7	67.9	1.4
Females	33.4	34.7	1.0
Breast (Females)	31.3	24.4	1.3
<50 years	8.6	4.9	1.8
50+ years	101.4	84.6	1.2
Prostate	53.6	22.6	2.4
Cervix	5.6	2.4	2.3
Larynx	2.7	1.2	2.3
Stomach	7.9	3.6	2.2
Esophagus	7.2	3.3	2.2
Multiple Myeloma	6.2	2.9	2.1
Oral Cavity and Pharynx	4.6	2.4	1.9
Corpus and Uterus, NOS	5.7	3.1	1.8
Liver and Intrahepatic Bile Duct	4.8	3.2	1.5
Pancreas	11.7	8.1	1.4
Colon and Rectum	22.8	16.8	1.4
Breast	31.3	24.4	1.3
Lung and Bronchus	59.2	48.9	1.2
Thyroid	0.3	0.3	1.0
Hodgkins Disease	0.5	0.5	1.0
Kidney and Renal Pelvis	3.5	3.6	1.0
Leukemias	5.9	6.4	0.9
Urinary Bladder	3.0	3.3	0.9
Ovary	6.3	7.8	0.8
Non-Hodgkins Lymphomas	4.9	7.1	0.7
Brain and Other Nervous System	2.5	4.4	0.6
Testis	0.1	0.3	0.3
Melanomas of the Skin	0.4	2.5	0.2

Data source: NCHS public-use data file for 1993-1997 deaths.  
Rates are per 100,000 and are age adjusted to 1970 US population.

## Cancer Incidence Rates By Race United States, 1993-1997

Cancer Site	Incidence Rates per 100,000		Ratio
	Blacks	Whites	Blacks/Whites
All Sites	455.2	401.9	1.1
Males	615.5	469.9	1.3
Females	340.9	355.0	1.0
All Sites Except Lung and Bronchus	382.3	345.5	1.1
Males	505.0	397.6	1.3
Females	295.1	310.4	1.0
Lung and Bronchus	72.9	56.4	1.3
Males	110.5	72.3	1.5
Females	45.7	44.5	1.0
Breast(Females)	102.8	115.3	0.9
<50 years	33.2	31.8	1.0
50+ years	317.4	373.1	0.9
Colon and Rectum	50.2	43.5	1.2
Colon excluding Rectum	38.6	31.2	1.2
Rectum and Rectosigmoid Junction	11.6	12.3	0.9
Multiple Myeloma	9.7	4.1	2.4
Esophagus	8.0	3.6	2.2
Stomach	11.5	5.8	2.0
Prostate	238.9	141.1	1.7
Larynx	6.4	3.8	1.7
Liver and Intrahepatic Bile Duct	5.3	3.2	1.7
Pancreas	13.9	8.4	1.7
Cervix Uteri	11.4	7.1	1.6
Oral Cavity and Pharynx	13.0	9.9	1.3
Lung and Bronchus	72.9	56.4	1.3
Kidney and Renal Pelvis	11.5	9.4	1.2
Colon and Rectum	50.2	43.5	1.2
Breast(females)	102.8	115.3	0.9
Hodgkins Disease	2.4	2.9	0.8
Leukemias	8.2	10.6	0.8
Non-Hodgkins Lymphomas	12.6	16.5	0.8
Ovary	10.5	15.4	0.7
Corpus and Uterus, NOS	15.3	22.6	0.7
Brain and Other Nervous System	3.8	6.5	0.6
Thyroid	3.0	5.5	0.5
Urinary Bladder	9.7	18.1	0.5
Testis	1.0	5.3	0.2
Melanomas of the Skin	0.9	15.6	0.1

Data source: NCI SEER Program.  
Rates are per 100,000 and are age adjusted to 1970 US population.

**The Prevalence of Cancer:  
Estimated Number of Persons  
Diagnosed With Cancer  
United States, 1997**

---

Primary Site	Estimated Prevalence		
	Total	Males	Females
<b>ALL SITES</b>	8,918,000	3,756,000	5,162,000
Brain and Other Nervous System	99,000	54,000	2,167,000
Breast	2,181,000	14,000	2,167,000
Cervix Uteri	209,000	0	209,000
Colon	853,000	394,500	458,500
Corpus Uteri	569,000	0	569,000
Hodgkin's Disease	168,000	89,000	79,000
Kidney and Renal Pelvis	224,000	136,000	88,000
Larynx	126,000	100,000	26,000
Leukemias	168,000	88,000	70,000
Lung and Bronchus	413,000	206,000	207,000
Melanomas of Skin	544,000	266,000	278,000
Non-Hodgkin's Lymphoma	332,000	166,000	166,000
Oral Cavity and Pharynx	208,000	127,000	81,000
Ovary	203,000	0	203,000
Pancreas	27,000	13,500	13,500
Prostate	1,247,000	1,247,000	0
Rectum	370,000	196,000	174,000
Stomach	77,000	43,000	34,000
Testis	142,000	142,000	0
Thyroid	233,000	57,000	176,000
Urinary Bladder	619,000	450,000	169,000
Childhood (0-14 yrs)	174,000	89,000	85,000

*Source: U.S. 1997 cancer prevalence rates are based on 1997 cancer prevalence rates from the Connecticut registry of the SEER program and 1/1/1997 population estimates based on the average of 1996 and 1997 population estimates from the U.S. Bureau of the Census. Connecticut prevalence rates are based on 1940-1996 cancer incidence and survival rates. These estimates can not be compared to previous estimates.*

# Fiscal Year 2000 Budget

(Dollars in Thousands)

---

## A. Actual Obligations Resulting From Appropriated Funds:

FY 2000 Appropriation	\$3,332,317
Real transfer from other NIH Institutes through the NIH Director's one percent transfer authority	-2,778
Real transfer to other HHS Agencies through Secretary's one percent transfer authority	-695
Rescission	-17,763
Lapse	0
<b>Actual Obligations Subtotal</b>	<b>3,311,081</b>

## B. Reimbursable Obligations:


AIDS Reimbursement from Office of the Director, NIH	916
Other Reimbursements	15,016
<b>Reimbursements</b>	<b>15,932</b>

## C. Total NCI Obligations: **\$3,327,013 \***

\*EXCLUDES Insight Awards to Stamp Out Breast Cancer(PAR-99-128). In FY 2000, there were 404 R21 applications and 32 R21 awards for \$3,499.

## Program Structure Fiscal Year 2000

(Dollars in Thousands)




Budget Activity	Amount	Percent
<b>Research:</b>		
Cancer Causation	\$814,064	24.6%
Detection and Diagnosis Research	214,993	6.5%
Treatment Research	822,677	24.8%
Cancer Biology	514,939	15.6%
<b>Subtotal Research</b>	<b>2,366,673</b>	<b>71.5%</b>
<b>Resource Development:</b>		
Cancer Centers Support	222,377	6.7%
Research Manpower Development	116,104	3.5%
Construction	3,500	0.1%
<b>Subtotal Resource Development</b>	<b>341,981</b>	<b>10.3%</b>
<b>Cancer Prevention and Control</b>	<b>366,550</b>	<b>11.1%</b>
<b>Program Management and Support</b>	<b>235,877</b>	<b>7.1%</b>
<b>*Total NCI</b>	<b>3,311,081</b>	<b>100.0%</b>

\*EXCLUDES Insight Awards to Stamp Out Breast Cancer(PAR-99-128). In FY 2000, there were 404 R21 applications and 32 R21 awards for \$3,499.

## Extramural Funds Fiscal Year 2000

(Dollars in Thousands)



Mechanism	Amount	Percent
<b>Contracts:</b>		
R& D Contracts	\$235,647	9.2%
Interagency Agreements	15,932	0.6%
Cancer Control Contracts	107,764	4.2%
Construction Contracts	2,012	0.1%
<b>Subtotal Contracts</b>	<b>361,355</b>	<b>14.1%</b>
<b>Grants:</b>		
Research Project Grants	1,528,001	59.5%
Cancer Centers/SPORES	221,350	8.6%
Training Activities	56,179	2.2%
Other Research Grants	232,676	9.1%
Cancer Control Grants	165,022	6.4%
Construction Grants	1,488	0.1%
<b>Subtotal Grants</b>	<b>2,204,716</b>	<b>85.9%</b>
<b>Total Extramural Funds</b>	<b>2,566,071</b>	<b>100.6%</b>
Total Intramural/RMS/Control Inhouse	745,010	
<b>*Total NCI</b>	<b>\$3,311,081</b>	

\*EXCLUDES Insight Awards to Stamp Out Breast Cancer(PAR-99-128). In FY 2000, there were 404 R21 applications and 32 R21 awards for \$3,499.

# NCI Obligations by Mechanism, Fiscal Year 2000

(Dollars in Thousands)

		Number	Amount	% of Total
<b>Research Project Grants</b>	Non-Competing	3,101	\$1,050,107	31.7%
	Administrative Supplements	(266)	23,721	0.7%
	Competing	1,119	387,083	11.7%
	Subtotal, without SBIR/STTR Grants	4,220	1,460,911	44.1%
	SBIR/STTR Grants-R41-44	306	67,090	2.0%
	<b>Subtotal, Research Project Grants</b>	<b>4,526</b>	<b>1,528,001</b>	<b>46.1%</b>
<b>Centers &amp; Spores</b>	Cancer Centers Grants-P30	60	169,068	5.1%
	SPOREs-P20/P50	22	52,282	1.6%
	<b>Subtotal, Centers</b>	<b>82</b>	<b>221,350</b>	<b>6.7%</b>
<b>Other Research</b>	Career Program			
	Temin & Minority Mentored Awards-K01	58	7,389	0.2%
	RCDA-K04	2	127	0.0%
	Preventive Oncology-K07	44	4,469	0.1%
	Clinical Investigator-K08	134	14,401	0.4%
	Physician Investigator-K11	2	181	0.0%
	Clinical Oncology-K12	21	7,670	0.2%
	Transitional Career Development-K22	4	560	0.0%
	Mentored Patient Oriented RCDA-K23	23	2,964	0.2%
	Mid-Career Invest. & Patient Orient. Res-K24	29	3,108	0.2%
	<b>Subtotal, Career Program</b>	<b>317</b>	<b>40,869</b>	<b>1.2%</b>
	Cancer Education Program-R25	83	16,821	0.5%
	Clinical Cooperative Groups-U10	140	144,608	4.4%
	Minority Biomedical Support-S06		3,341	0.1%
	Scientific Evaluation-U09/T09	2	4,664	0.1%
	Continuing Education	3	402	0.0%
	Resource Grants-R24/U24	34	20,344	0.6%
	Conference Grants-R13	74	1,627	0.0%
	<b>Subtotal, Other Research Grants</b>	<b>653</b>	<b>232,676</b>	<b>7.0%</b>
<b>Subtotal, Research Grants</b>		<b>5,261</b>	<b>1,982,027</b>	<b>59.9%</b>
<b>NRSA Fellowships</b>	<i>Trainees:</i>	<b>1,600</b>	<b>56,179</b>	<b>1.7%</b>
<b>R&amp;D Contracts</b>	R&D Contracts	135	251,173	7.6%
	SBIR Contracts	4	406	0.0%
	<b>Subtotal, Contracts</b>	<b>139</b>	<b>251,579</b>	<b>7.6%</b>
<b>Intramural Research:</b>	Program		402,984	12.2%
	NIH Management Fund		104,801	3.2%
	<b>Subtotal, Intramural Research</b>	<i>FTEs:</i>	<b>1,790</b>	<b>507,785</b>
<b>RMS</b>	Research Mgmt and Support	793	103,825	3.1%
	NIH Management Fund		16,761	0.5%
	<b>Subtotal, RMS</b>	<i>FTEs:</i>	<b>793</b>	<b>120,586</b>
<b>Cancer Prevention and Control:</b>	Cancer Control Grants	210	165,022	5.0%
	Cancer Control Contracts	170	107,764	3.3%
	Inhouse		104,948	3.2%
	NIH Management Fund		11,691	0.4%
	<b>Subtotal, Prevention and Control</b>	<i>FTEs:</i>	<b>211</b>	<b>389,425</b>
<b>Construction</b>			3,500	0.1%
<b>*Total NCI</b>	<i>FTEs:</i>	<b>2,794</b>	<b>3,311,081</b>	<b>100.0%</b>

\*EXCLUDES Insight Awards to Stamp Out Breast Cancer(PAR-99-128). In FY 2000, there were 404 R21 applications and 32 R21 awards for \$3,499.

# Division Obligations by Mechanisms, Fiscal Year 2000


(Dollars in Thousands)

DBS	DCS	DCEG	DCTD	DCB	DCCPS	DCP	DEA	OD	Research Grants	Program Support
									\$1,050,107	
									23,721	
									387,083	
									1,460,911	
									67,090	
									<b>1,528,001</b>	
								\$169,068		
								52,282		
								<b>221,350</b>		
								7389		
								127		
								4,469		
								14,401		
								181		
								7,670		
								560		
								2,964		
								3,108		
								<b>40,869</b>		
								16,821		
									144,608	
									3,341	
									4,664	
									402	
									20,344	
									1,627	
								<b>57,690</b>	<b>174,986</b>	
								<b>279,040</b>	<b>1,702,987</b>	
								<b>56,179</b>		
		\$6,695	\$75,669	\$4,394	\$19,147			110,715		\$34,553
			199		207					
		<b>6,695</b>	<b>75,868</b>	<b>4,394</b>	<b>19,354</b>			<b>110,715</b>		<b>34,553</b>
\$180,449	\$126,394	52,548	2,745					33,983		6,865
										104,801
<b>180,449</b>	<b>126,394</b>	<b>52,548</b>	<b>2,745</b>					<b>33,983</b>		<b>111,666</b>
			23,059	7,660			12,490	47,227		13,389
										16,761
			<b>23,059</b>	<b>7,660</b>			<b>12,490</b>	<b>47,227</b>		<b>30,150</b>
			9,798		53,638	\$92,465		9,121		
		2,853	264		23,037	58,777		22,833		
	4,936	7,557	4,028		18,159	14,996	118	52,317		2,837
										11,691
	<b>4,936</b>	<b>10,410</b>	<b>14,090</b>		<b>94,834</b>	<b>166,238</b>	<b>118</b>	<b>84,271</b>		<b>14,528</b>
								3,500		
<b>180,449</b>	<b>131,330</b>	<b>69,653</b>	<b>115,762</b>	<b>12,054</b>	<b>114,188</b>	<b>166,238</b>	<b>12,608</b>	<b>614,915</b>	<b>1,702,987</b>	<b>190,897</b>



# NIH Management Fund Reimbursement Fiscal Year 2000

(Dollars in Thousands)



DISTRIBUTION OF NCI PAYMENT	Amount	Share of NCI
Clinical Center	\$67,967	51.0%
Center for Scientific Review	5,221	3.9%
Center for Information Technology	6,575	4.9%
GSA Rental Payments for Space	14,211	10.7%
Other Research Services	35,109	26.3%
Other OD	4,170	3.1%
Total, NCI Payment	133,253	100.0%
Other NIH Institutes Management Fund	379,482	
NIH Management Fund	\$512,735	

The Management Fund provides for the financing of certain common research and administrative support activities which are required in the operations of NIH:

*Clinical Center:* Admissions and followup, anesthesiology, diagnostic x-ray, nuclear medicine, clinical pathology, blood bank, rehabilitation medicine, pharmacy, medical records, nursing services, patient nutrition service, housekeeping services, laundry, and social work

*Center for Scientific Review:* Initial scientific review of applications, assignment of research grant applications to institutes

*Center for Information Technology:* Research and development program in which concepts and methods of computer science are applied to biomedical problems

*GSA Rental Payments for Space:* Building rental including utilities and guard services

*Other Research Services:* Procurement, safety, engineering, biomedical engineering, veterinary resources, and library

## Special Sources of Funds

### CRADAs

As a result of the Federal Technology Transfer Act of 1986 (PL 99-502), government laboratories are authorized to enter into Cooperative Research and Development Agreements (CRADAs) with private sector entities. Licensing agreements are usually incorporated into the CRADA document which addresses patent rights attributable to research supported under the CRADA.

CRADA Receipts Deposited to the U.S. Treasury  
(Dollars in Thousands)

Fiscal Year	Carryover from Prior Year	Collections	Obligations
1992	\$101	\$1,627	\$466
1993	1,262	2,509	1,582
1994	2,189	2,248	1,917
1995	2,570	2,653	1,478
1996	3,745	2,229	1,394
1997	4,580	13,434	6,631
1998	11,383	5,351	7,266
1999	9,468	3,646	4,707
2000	8,240	2,743	4,616
2001	6,367		

### Royalty Income

NCI retains a portion of the royalty income generated by the patents related to NCI-funded research. A major portion of this royalty income is used to reward employees of the laboratory, further scientific exchange and for education and training in accordance with the terms of the Federal Technology Transfer Act (PL 99-502). Receipts are also used to support costs associated with processing and collecting royalty income and for technology transfer efforts in NCI and NIH.

Royalty Income Funding History  
(Dollars in Thousands)

Years	Collections*	Inventor Payments	Other
1991/1992	\$2,084	\$431	\$1,653
1992/1993	2,105	451	1,654
1993/1994	5,700	983	4,717
1994/1995	11,244	1,235	10,009
1995/1996	9,031	953	8,078
1996/1997	13,598	2,175	11,423
1997/1998	9,814	2,321	7,493
1998/1999	22,716	5,084	17,632
1999/2000	21,160	4,695	16,465
2000/2001	37,040	4,811	32,229

\* Does not include assessments by NIH.

### Breast Cancer Emergency Supplement – Flood Money

The Emergency Supplement Appropriations Act (PL 105-18) of June 1997, appropriated \$15,000,000 to the Department of Health and Human Services to support high priority health research in the area of environmental influences on breast cancer. \$12,000,000 of the funds were transferred to NCI to support breast cancer research. In FY 1999, NCI obligated \$9,748,403. In FY 2000, NCI obligated \$215,400 with the remaining \$2,423,481 to be used in FY 2001.

### Stamp Out Breast Cancer

The Stamp Out Breast Cancer Act (PL 105-41) was established in August 1997 and extended in July 2000 (PL 106-253). This act allows postal customers to contribute to funding for breast cancer research through their voluntary purchases of special rate postage stamps from U.S. Postal Service. The Act required the USPS to transfer 70% to NIH and 30% to the DOD of the funds collected above the postage costs and administrative costs. As of July 2000, NCI has received \$7,251,243. NCI will use the funds to fund research projects directed towards breast cancer, specifically, those grants in response to the NCI RFA for "Insight Awards to Stamp Out Breast Cancer." In FY 2000, 34 R21 grants have been awarded among 398 R21 applications for \$3,498,708 for one year. The second year of the insight awards will be paid in FY 2001.

## Research Funding for Various Research Areas


(Dollars in Millions)

The National Cancer Institute reports how appropriated funds are spent in a number of different categories or classifications including specific cancer sites, cancer types, diseases related to cancer, as well as types of research mechanisms. The table below represents funding levels for frequently requested research areas. These research areas do not represent the entire NCI research portfolio. Funding for these areas can overlap and do not add to the total NCI budget. For example, dollars for a clinical trial on breast cancer research would be included in both the Breast Cancer and the Clinical Trials lines in the table below. Similarly, a basic cancer research project may be relevant to cervical, uterine and ovarian cancers and relevant funding would be included in the figures for all three sites.

	<b>1996</b>	<b>1997</b>	<b>1998</b>	<b>1999</b>	<b>2000</b>
Total NCI Budget	\$2,254.9	\$2,389.1	\$2,551.3	\$2,891.0	\$3,311.1
AIDS	225.4	224.7	225.9	239.2	244.1
Brain & ONS	41.6	46.1	54.3	63.5	71.9
Breast Cancer	317.5	332.0	348.7	387.2	438.7
Cervical Cancer	51.6	55.8	58.0	66.3	67.0
Colorectal Cancer	98.0	103.2	121.0	152.9	175.8
Head and Neck Cancers	34.3	38.5	41.9	45.9	47.0
Hodgkins Disease	8.0	8.1	8.3	8.2	9.4
Leukemia	79.3	91.2	103.4	122.2	141.7
Liver Cancer	31.4	35.3	38.1	39.8	46.2
Lung Cancer	119.4	132.4	139.8	151.0	175.0
Melanoma	36.0	43.3	50.3	60.1	67.9
Non Hodgkin's Lymphoma	49.9	52.7	57.1	66.2	70.4
Ovarian Cancer	36.5	41.7	40.8	56.5	65.5
Pancreatic Cancer	8.1	10.2	14.2	17.3	20.0
Prostate Cancer	71.7	82.3	86.9	135.7	203.2
Stomach Cancer	7.6	9.3	8.2	7.6	8.2
Uterine Cancer	8.1	8.1	12.2	13.8	16.0

# Research Project Grants Number of Awards Fiscal Years 1991-2000

*Includes Small Business Innovation Research Awards*



# RPGs Requested and Awarded Fiscal Years 1991-2000

(Dollars in Thousands)

Fiscal Year	Type	Requested		Awarded		Success Rate	
		No.	Amt.	No.	Amt.		
1991	Competing	New	2,195	\$512,665	513	\$102,364	27.6%
		Renewal	837	286,858	323	94,231	
		Supplement	8	1,161	4	421	
		Subtotal	3,040	800,684	840	197,016	
	Non-Competing				2,207	594,532	
	Total			<b>3,047</b>	<b>791,548</b>		
1992	Competing	New	2,508	\$612,369	664	\$119,091	32.2%
		Renewal	815	332,428	398	133,413	
		Supplement	23	3,704	17	1,347	
		Subtotal	3,346	948,501	1,079	253,851	
	Non-Competing				2,231	620,006	
	Total			<b>3,310</b>	<b>873,857</b>		
1993	Competing	New	3,173	\$746,912	644	\$114,227	23.9%
		Renewal	891	328,657	340	107,949	
		Supplement	75	8,554	7	1,698	
		Subtotal	4,139	1,084,123	991	223,874	
	Non-Competing				2,346	692,436	
	Total			<b>3,337</b>	<b>916,310</b>		
1994	Competing	New	3,643	\$787,824	657	\$118,403	21.1%
		Renewal	935	342,068	308	110,723	
		Supplement	20	3,311	4	733	
		Subtotal	4,598	1,133,203	969	229,859	
	Non-Competing				2,436	704,665	
	Total			<b>3,405</b>	<b>934,524</b>		
1995	Competing	New	3,345	\$789,560	645	\$119,760	23.3%
		Renewal	1,048	403,577	375	127,065	
		Supplement	21	7,502	10	1,537	
		Subtotal	4,414	1,200,639	1,030	248,362	
	Non-Competing				2,333	704,374	
	Total			<b>3,363</b>	<b>952,736</b>		
1996	Competing	New	3,071	\$733,313	682	142,249	27.5%
		Renewal	947	367,270	422	139,995	
		Supplement	10	1,921	5	694	
		Subtotal	4,028	1,102,504	1,109	282,938	
	Non-Competing				2,381	751,592	
	Total			<b>3,490</b>	<b>1,034,530</b>		
1997	Competing	New	3,328	\$828,653	815	160,763	29.2%
		Renewal	815	354,054	392	146,912	
		Supplement	14	3,136	5	755	
		Subtotal	4,157	1,185,843	1,212	308,430	
	Non-Competing				2,532	814,885	
	Total			<b>3,744</b>	<b>1,123,315</b>		
1998	Competing	New	3,054	\$797,477	847	189,746	32.8%
		Renewal	697	283,562	382	137,764	
		Supplement	18	4,299	6	1,421	
		Subtotal	3,769	1,085,338	1,235	328,931	
	Non-Competing				2,723	901,845	
	Total			<b>3,958</b>	<b>1,230,776</b>		
1999	Competing	New	3,905	\$1,091,110	1,088	237,187	31.8%
		Renewal	757	340,075	390	145,623	
		Supplement	12	3,882	6	2,353	
		Subtotal	4,674	1,435,067	1,484	385,163	
	Non-Competing				2,867	976,610	
	Total			<b>4,351</b>	<b>1,361,773</b>		
2000	Competing	New	4,116	\$1,253,002	957	251,628	27.2%
		Renewal	839	435,207	392	175,908	
		Supplement	11	2,379	2	231	
		Subtotal	4,966	1,690,588	1,351	427,767	
	Non-Competing				3,175	1,100,234	
	Total			<b>4,526</b>	<b>1,528,001</b>		

Includes Small Business Innovation Awards.


Success rate is the number of awarded grants divided by the number of awards requested.

The requested data excludes applications not recommended for further review.

# RPG Awards by Activity Code Fiscal Years 1991-2000

(Dollars in Thousands; activity code descriptions on next page)

		R01	P01	R35	R37	R29	RFA	U01	R03	R21	R33	R15	R55	SBIR/S TTR	TOTAL
1991	#	1,949	165	84	163	316	154	85						131	3,047
	\$	381,932	190,470	62,137	43,687	29,494	37,435	32,431						13,962	791,548
1992	#	2,050	183	76	162	309	208	123						199	3,310
	\$	424,954	205,330	59,878	47,414	29,726	45,107	44,171						17,277	873,857
1993	#	1,955	176	75	166	291	282	171					6	215	3,337
	\$	430,203	202,852	61,337	51,633	29,053	63,267	56,199					1,365	20,401	916,310
1994	#	1,914	163	72	154	312	319	232	46	5			9	179	3,405
	\$	434,612	184,852	61,369	48,699	32,610	70,879	75,444	2,393	353			540	22,773	934,524
1995	#	1,808	149	67	142	342	314	253	44	34			19	191	3,363
	\$	439,122	171,524	63,032	45,125	36,014	72,409	81,771	2,488	7,640			1,126	32,485	952,736
1996	#	1,964	144	65	110	388	268	226	85	46			14	180	3,490
	\$	504,398	182,609	62,550	37,070	41,170	66,102	88,962	5,443	9,599			984	35,643	1,034,530
1997	#	2,194	149	63	90	446	195	169	101	63			21	253	3,744
	\$	583,116	202,317	62,892	30,950	47,413	48,148	81,193	6,411	12,269			1,450	47,156	1,123,315
1998	#	2,454	160	57	75	485	132	157	97	76		2	14	249	3,958
	\$	672,873	228,854	57,712	27,212	52,136	42,750	79,370	6,069	11,782		127	684	51,207	1,230,776
1999	#	2,796	169	38	71	413	261	31	108	159	6	2	6	291	4,351
	\$	775,961	249,583	38,585	27,377	45,361	112,868	21,319	7,355	22,548	2,079	200	620	57,917	1,361,773
2000	#	3,011	179	21	60	314	269	18	100	223	20	0	5	306	4,526
	\$	898,764	286,234	19,413	24,688	34,769	132,872	13,617	7,034	32,897	10,074	99	450	67,090	1,528,001



## Activity Code Descriptions

<b>R01</b>	<b>Research Project (Traditional)</b> discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his/her specified interest and competencies.
<b>P01</b>	<b>Research Program Projects</b> broadly based, multidisciplinary, often long-term, research program which has a specific major objective or a basic theme. A program project is directed toward a range of problems having a central research focus in contrast to the usually narrower thrust of the traditional research project.
<b>R35</b>	<b>Outstanding Investigator Grants</b> long-term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential in a categorical program area.
<b>R37</b>	<b>Method to Extend Research in Time (MERIT) Award</b> long-term grant support to investigators whose research competence and productivity are distinctly superior and who are highly likely to continue to perform in an outstanding manner. Investigators may not apply for a MERIT award. Program staff and/or members of the cognizant National Advisory Council/Board will identify candidates for the MERIT award during the course of review of competing research grant applications prepared and submitted in accordance with regular PHS requirements.
<b>R29</b>	<b>First Independent Research Support and Transition (FIRST) Award</b> sufficient initial period of research support for newly independent biomedical investigators to develop their research capabilities and demonstrate the merit of their research ideas.
<b>RFA</b>	<b>Request for Applications</b> A formal statement inviting grant or cooperative agreement applications in a well-defined scientific area to accomplish specific program purposes and indicates the amount of funds set aside for the competition and/or the estimated number of awards to be made.
<b>U01</b>	<b>Research Project (Cooperative Agreement)</b> discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his/her specific interest and competencies.
<b>R03</b>	<b>Small Grants</b> research support specifically limited in time and amount for studies in categorical program areas. Small grants provide flexibility for initiating studies, which are generally for preliminary short-term projects and are non-renewable.
<b>R21</b>	<b>Exploratory/Developmental Grants Phase I</b> development of new research activities in categorical program areas. Support generally is restricted in level of support and in time.
<b>R33</b>	<b>Exploratory/Developmental Grants Phase II</b> development of new research activities in categorical program areas. Support generally is restricted in level of support and in time.
<b>R15</b>	<b>Academic Research Enhancement Award (AREA)</b> to domestic health professional schools and other institutions offering baccalaureate or advanced degrees in health sciences, except those that have received NIH research grants and/or cooperative agreements. Supports feasibility studies and other small-scale research projects.
<b>R55</b>	<b>Shannon Awards</b> limited support to scientists whose research applications fall short of the cutoff for funding yet are at the "margin of excellence" whereby the perceived quality of the grant is statistically indistinguishable from grants that are funded.
<b>R41</b>	<b>Small Business Technology Transfer (STTR) Grants - Phase I</b> establish the technical merit and feasibility of R&D ideas which may ultimately lead to a commercial product(s) or service(s).
<b>R42</b>	<b>Small Business Technology Transfer (STTR) Grants - Phase II</b> establish the technical merit and feasibility of R&D ideas which may ultimately lead to a commercial product(s) or service(s).
<b>R43</b>	<b>Small Business Innovation Research (SBIR) Grants - Phase I</b> projects limited in time and amount, to establish the technical merit and feasibility of R&D ideas which may ultimately lead to a commercial product(s) or service(s).
<b>R44</b>	<b>Small Business Innovation Research (SBIR) Grants - Phase II</b> in-depth development of R&D ideas whose feasibility has been established in Phase I and which are likely to result in commercial products or services.

## Cancer Centers by State (P30 Core Grants), Fiscal Year 2000

(Dollars in thousands)

State	Grantee Institution	Type	Amount
Alabama	Univ of Alabama at Birmingham	Comprehensive	\$4,633
Arizona	Univ of Arizona	Comprehensive	2,464
California	Beckman Research Institute/City of Hope	Comprehensive	2,168
	Burnham Institute	Lab/Basic	3,008
	Salk Institute	Lab/Basic	2,404
	Univ of California at Los Angeles	Comprehensive	3,183
	Univ of California at San Diego	Clinical	1,111
	Univ of California at Irvine	Comprehensive	1,847
	Univ of Southern California	Comprehensive	4,237
	Univ of California San Francisco	Comprehensive	1,281
Colorado	Univ of Colorado Health Sciences Center	Comprehensive	2,788
Connecticut	Yale Univ	Comprehensive	1,988
District of Columbia	Georgetown Univ	Comprehensive	3,006
Florida	Univ of South Florida	Clinical	1,097
Hawaii	Univ of Hawaii at Manoa	Clinical	2,097
Illinois	Northwestern Univ-Robert H. Lurie Cancer Center	Comprehensive	1,654
	Univ of Chicago	Comprehensive	2,467
Indiana	Indiana Univ.	Clinical	1,222
	Purdue Univ West Lafayette	Lab/Basic	1,069
Iowa	University of Iowa	Comprehensive	1,221
Maine	Jackson Laboratory	Lab/Basic	1,925
Maryland	Johns Hopkins Univ	Comprehensive	4,264
Massachusetts	Dana-Farber Cancer Institute	Comprehensive	10,825
	Massachusetts Institute of Technology	Lab/Basic	2,336
Michigan	Univ of Michigan at Ann Arbor	Comprehensive	3,084
	Karmanos Cancer Institute/Wayne State Univ	Comprehensive	0
Minnesota	Mayo Foundation	Comprehensive	3,034
	Univ of Minnesota Twin Cities	Comprehensive	1,413
Nebraska	Univ of Nebraska Medical Center	Lab/Basic	1,074
New Hampshire	Dartmouth College	Comprehensive	1,749
New Jersey	Robert Wood Johnson Medical School	Clinical	2,183
New York	Cold Spring Harbor Laboratory	Lab/Basic	3,471
	Columbia Univ New York	Comprehensive	3,530
	Kaplan Cancer Center/NYU	Comprehensive	1,476
	Roswell Park Cancer Institute	Comprehensive	1,206
	Memorial Sloan-Kettering Institute	Comprehensive	5,876
	American Health Foundation	Lab/Basic	2,268
	Albert Einstein College of Medicine/Yeshiva Univ	Comprehensive	4,131
North Carolina	Duke Univ	Comprehensive	5,544
	Univ of North Carolina Chapel Hill	Comprehensive	5,154
	Wake Forest Univ/Bowman Gray Sch. Of Medicine	Comprehensive	0
Ohio	Case Western Reserve Univ	Comprehensive	2,088
	Ohio State Univ	Comprehensive	2,397
Oregon	Oregon Health Sciences Univ	Clinical	1,203
Pennsylvania	Fox Chase Cancer Center	Comprehensive	7,140
	Thomas Jefferson University	Clinical	251
	Univ of Pennsylvania	Comprehensive	4,980
	Univ of Pittsburgh	Comprehensive	3,789
	Wistar Institute	Lab/Basic	2,198
Tennessee	St. Jude Children's Research Hospital	Clinical	3,836
	Vanderbilt Univ	Clinical	3,274
Texas	San Antonio Cancer Institute	Comprehensive	2,191
	M.D. Anderson Cancer Center/Univ. of Texas	Comprehensive	5,598
Utah	Huntsman Cancer Institute/Univ of Utah	Clinical	1,144
Vermont	Univ of Vermont	Comprehensive	280
Virginia	Univ of Virginia/Health Sciences Center	Clinical	1,991
	VCU/Massey Cancer Center	Clinical	346
Washington	Fred Hutchinson Cancer Research Center	Comprehensive	7,551
Wisconsin	Univ of Wisconsin Madison	Comprehensive	2,963
	McArdle Laboratory for Cancer Research/Univ. of Wisconsin	Lab/Basic	2,449
	Total P30s	60	165,158
	Planning Grants		1,265
	NCI Co-funded Awards with other NIH Institutes		2,645
Total Cancer Centers			169,068



## Specialized Programs of Research Excellence, Fiscal Year 2000

(Dollars in thousands)

In 1992, the NCI established the Specialized Programs of Research Excellence (SPORE). This program promotes interdisciplinary research and speeds the bidirectional exchange between basic and clinical science to move basic research findings from the laboratory to applied settings involving patients and populations. The goal of the SPORE program is to bring to clinical care settings novel ideas that have the potential to reduce cancer incidence and mortality, and to improve survival, and the quality of life.

Laboratory and clinical scientists work collaboratively to plan, design and implement research programs that impact on cancer prevention, detection, diagnosis, treatment and control. To facilitate this research, each SPORE develops and maintains specialized resources that benefit all scientist working on the specific cancer site, as well as SPORE scientists. An additional SPORE element is a career development program that recruits scientists both within and outside the SPORE institution to enlarge the cadre of laboratory and clinical scientists dedicated to translational research on human cancer. SPOREs meet annually to share data, assess research progress, identify new research opportunities and establish research priorities.


Mechanism	Site	No.	Amount
SPOREs	Breast	9	\$19,436
	Gastrointestinal	2	4,245
	Lung	3	6,400
	Prostate	4	10,335
	Ovarian	4	7,790
	Total P50	22	48,206
Supplement	DNA Array		1,209
	Mammalian Models		439
	Minority Biomedical Supplements		339
	Total Supplement		1,987
Co-funded	Urology with NIDDK	(3)	523
	Oral with NIDCR	(3)	1,166
	Genome with NHGRI	(1)	400
	Total Cofunded	(7)	2,089
Total		22	\$52,282

### NOTE:

Counted P50s when they are funded as a supplement (T-3) with no other non-competing or competing support.


## NRSA Predoctoral and Postdoctoral Trainees Fiscal Years 1991-2000

(Full Time Trainee Positions)



# Construction/Renovation Funding Fiscal Years 1991-2000

(Dollars in Thousands)



# Grant and Contract Awards by State Fiscal Year 2000

(Dollars in thousands)

State	Grants		Contracts		Total NCI		State
	No	Amount	No	Amount	No	Amount	
Alabama	61	\$27,954	17	\$8,520	78	\$36,474	Alabama
Alaska	1	184	0		1	184	Alaska
Arizona	55	26,378	2	486	57	26,864	Arizona
Arkansas	12	5,668	0	0	12	5,668	Arkansas
California	671	301,170	23	127,571	694	428,741	California
Colorado	92	30,774	2	2,327	94	33,100	Colorado
Connecticut	78	25,513	2	3,467	80	28,980	Connecticut
Delaware	4	1,399	0	0	4	1,399	Delaware
District of Columbia	65	32,264	5	1,820	70	34,083	District of Columbia
Florida	91	25,977	2	1,571	93	27,548	Florida
Georgia	44	12,581	0	1,742	44	14,323	Georgia
Hawaii	20	12,708	1	2,815	21	15,524	Hawaii
Idaho	0	0	0	0	0	0	Idaho
Illinois	174	82,811	21	6,320	195	89,131	Illinois
Indiana	43	13,335	1	3	44	13,338	Indiana
Iowa	36	8,542	2	4,760	38	13,302	Iowa
Kansas	19	5,281	4	2,595	23	7,876	Kansas
Kentucky	32	8,135	2	2,033	34	10,168	Kentucky
Louisiana	32	7,130	0	0	32	7,130	Louisiana
Maine	7	3,320	0	0	7	3,320	Maine
Maryland	166	74,357	92	115,719	258	190,076	Maryland
Massachusetts	479	219,081	4	1,214	483	220,294	Massachusetts
Michigan	163	55,764	5	11,507	168	67,271	Michigan
Minnesota	137	52,943	4	1,802	141	54,745	Minnesota
Mississippi	4	312	0	0	4	312	Mississippi
Missouri	88	26,638	6	3,615	94	30,253	Missouri
Montana	4	909	0	0	4	909	Montana
Nebraska	23	9,233	0	0	23	9,233	Nebraska
Nevada	4	1,002	0	0	4	1,002	Nevada
New Hampshire	36	15,517	1	120	37	15,637	New Hampshire
New Jersey	89	32,091	1	1,948	90	34,039	New Jersey
New Mexico	27	8,588	0	2,371	27	10,959	New Mexico
New York	488	201,266	13	8,201	501	209,467	New York
North Carolina	173	72,227	11	6,413	184	78,639	North Carolina
North Dakota	2	493	0	0	2	493	North Dakota
Ohio	178	56,042	15	6,042	193	62,084	Ohio
Oklahoma	12	3,135	1	82	13	3,217	Oklahoma
Oregon	46	14,846	1	430	47	15,277	Oregon
Pennsylvania	369	170,808	9	6,120	378	176,928	Pennsylvania
Rhode Island	40	11,683	0	0	40	11,683	Rhode Island
South Carolina	30	7,319	0	0	30	7,319	South Carolina
South Dakota	2	553	0	0	2	553	South Dakota
Tennessee	131	45,384	1	32	132	45,416	Tennessee
Texas	345	157,135	11	8,795	356	165,930	Texas
Utah	42	15,064	2	2,995	44	18,059	Utah
Vermont	16	7,775	0	0	16	7,775	Vermont
Virginia	91	34,472	3	2,355	94	36,827	Virginia
Washington	203	108,617	5	6,759	208	115,376	Washington
West Virginia	5	867	1	1,364	6	2,231	West Virginia
Wisconsin	88	32,445	4	1,922	92	34,366	Wisconsin
Wyoming	0	0	0	0	0	0	Wyoming
Total	5,018	2,067,689	274	355,837	5,292	2,423,525	Total
Guam		72	0			72	Guam
Puerto Rico	1	482	0			482	Puerto Rico
Total	5,019	2,068,243	274	355,837	5,293	2,424,080	Total

Excludes Manpower Development and foreign grants

## Grant and Contract Awards by Country Fiscal Year 2000

(Dollars in Thousands)

Country	Grant		Contract		Total NCI		Country
	No	Amount	No	Amount	No	Amount	
Australia	10	\$1,980			10	\$1,980	Australia
Belgium	1	414			1	414	Belgium
Canada	21	4,221			21	4,221	Canada
China			1	25	1	25	China
Costa Rica			1	1,410	1	1,410	Costa Rica
Denmark	1	644	1	49	2	693	Denmark
France	4	927			4	927	France
Germany	1	87			1	87	Germany
India	1	187			1	187	India
Israel	4	557			4	557	Israel
Italy	1	354			1	354	Italy
Jamaica			1	922	1	922	Jamaica
Japan			1	184	1	184	Japan
Mexico	1	52			1	52	Mexico
Netherlands	2	185			2	185	Netherlands
New Zealand			1	50		50	New Zealand
Poland			1	495	1	495	Poland
South Africa	1	187			1	187	South Africa
Spain	1	180				180	Spain
Sweden	2	83	1	101	3	184	Sweden
Switzerland	1	10			1	10	Switzerland
Trinidad/Tobago			1	270	1	270	Trinidad/Tobago
United Kingdom	6	705			6	705	United Kingdom
<b>Total Foreign</b>	<b>58</b>	<b>10,773</b>	<b>9</b>	<b>3,506</b>	<b>65</b>	<b>14,279</b>	

## Institutions Receiving More than \$15 Million in NCI Support, FY 2000

(Dollars in thousands)

State	Institution	Grants	Contracts	Construction	Total NCI
Alabama	Univ of Alabama System	\$25,213	\$5,368		\$30,581
Arizona	Univ of Arizona	25,249	486		25,735
California	Nat'l Childhood Can. Foundation	16,109			16,109
	Science Applications Int'l Corp		107,730		107,730
	Scripps Research Institute	15,440			15,440
	Stanford Univ	35,380			35,380
	Univ of California	129,484	2,661		132,146
	Univ of Southern California	27,887	2,357		30,244
Colorado	Univ of Colorado System	14,950	1,325	\$1,488	17,763
Connecticut	Yale Univ	22,536	1,393		23,929
Dist of Columbia	Georgetown Univ	18,974	836		19,811
Florida	State Univ System of Florida	18,557			18,557
Illinois	Northwestern Univ	23,085	842		23,927
	Univ of Chicago	28,326			28,326
	Univ of Illinois System	13,798	3,193		16,991
Maryland	Johns Hopkins Univ	56,364	1,560		57,924
	Westat, Inc.		18,981		18,981
Massachusetts	Brigham & Women's Hospital	25,544			25,544
	Dana- Faber Cancer Institute	51,072			51,072
	Harvard Univ	35,706			35,706
	Mass General Hospital	28,739			28,739
Michigan	Univ of Michigan	37,523	1,457		38,979
	Wayne State Univ	10,837	6,897		17,734
Minnesota	Mayo Foundation	28,425	327		28,753
	Univ of Minnesota	23,838	1,475		25,313
Missouri	Washington Univ	19,599	1,514		21,113
New Hampshire	Dartmouth College	15,589	120		15,710
New York	City Univ of New York	16,474			16,474
	Columbia Univ	23,363			23,363
	Memorial Sloan-Kettering Can Ctr	45,198	1,845		47,044
	New York Univ	16,312			16,312
	Roswell Park Cancer Institute	18,555			18,555
	Yeshiva Univ	21,715			21,715
North Carolina	Duke Univ	38,401	1,261		39,661
	Univ of North Carolina System	30,366	130		30,496
Ohio	Case Western Reserve Univ	23,856	1,754		25,610
	Ohio State Univ	18,785	1,748		20,533
Pennsylvania	Fox Chase Cancer Center	27,300	2,656		29,956
	NSABP Foundation, Inc.	17,866			17,866
	Thomas Jefferson Univ	19,912			19,912
	Univ of Pennsylvania	43,103	933		44,036
	Univ of Pittsburgh	32,625	2,021		\$34,646
Tennessee	St. Jude Children's Res. Hosp	20,598			20,598
	Vanderbilt Univ	23,705			23,705
Texas	Baylor College of Medicine	29,228			29,228
	CTRRC Research Foundation	31,640			31,640
	Univ of Texas System	96,878	8,704		105,582
Utah	Utah State Higher Ed. System	14,369	2,995		17,363
Virginia	American College of Radiology	15,377			15,377
Washington	Fred Hutchinson Cancer Research	69,323	5,611		74,934
	Univ of Washington	23,476	1,148		24,625
Wisconsin	Univ of Wisconsin System	26,737	1,509		28,247
	Total	1,493,387	190,838	1,488	1,685,712

## Appropriations of the NCI 1938-2001

(In Whole Dollars)

---

<b>1938 - 1969</b>	<b>\$1,875,699,720</b>	
<b>1970 - 1979</b>	<b>6,073,870,500</b>	
<b>1980 - 1989</b>	<b>11,958,860,000</b>	
1990.....	1,664,000,000	<i>prior to reductions in PL 101-166 (-\$6,839,000) and PL101-239 (-\$22,829,000).</i>
1991.....	1,766,324,000	<i>prior to reductions in PL 101-517 (-\$8,972,000 for salary and expense reduction; -\$42,568,000 for across-the-board reduction).</i>
1992.....	1,989,278,000	<i>prior to reductions in PL 102-170 (-\$21,475,000 for salary and expense reduction; -\$1,262,000 for travel reduction; \$15,000,000 transferred to other institutes for cancer research).</i>
1993.....	2,007,483,000	<i>prior to reductions in PL 102-294 (-\$16,060,000 for .8% reduction to all line items, -\$9,933,000 for S&amp;E reduction, -\$139,000 for consultant services reduction).</i>
1994.....	2,082,267,000	<i>prior to reduction in PL103-211 (-\$5,885,000 administration reduction).</i>
1995.....	2,135,119,000	<i>prior to reductions in PL 103-211 (-\$1,883,000 for Procurement reduction; -\$116,000 for SLUC reduction; -\$1,052,000 for Bonus Pay reduction). Includes \$218,199,000 of AIDS funding.</i>
1996.....	2,251,084,000	<i>Includes \$225,790,000 of AIDS funding.</i>
1997.....	2,382,532,000	<i>Includes \$224,983,000 of AIDS funding.</i>
1998.....	2,547,314,000	<i>prior to reductions in PL 105-119 (-\$4,755,000 via the Secretary's 1% transfer authority). Includes \$8,699,000 transferred via the NIH Director's 1% transfer authority, \$41,000 transfer from U.S. Dept of State in PL 105-119, and \$226,414,000 of AIDS funding.</i>
1999.....	2,927,187,000	<i>prior to reductions in PL 106-51 (-\$1,940,000 for travel and admin expenses). Includes -\$931,000 transferred via the Secretary 1% transfer authority, and -\$6,259,000 transferred via the NIH Director's 1% transfer authority, and \$239,190,000 of AIDS funding.</i>
<b>1990 - 1999</b>	<b>21,752,588,000</b>	
2000.....	3,332,317,000	<i>Appropriation prior to reductions in PL 106-113 (-\$17,763,000 for across the board reduction). Includes \$245,804,000 of AIDS funding.</i>
<b>1938-2000</b>	<b>44,993,335,220</b>	

## By-Pass Budget Requests Fiscal Years 1973-2002

*(In Whole Dollars)*


---

<b>Fiscal Year</b>	<b>Request</b>
1973.....	\$550,790,000
1974.....	640,031,000
1975.....	750,000,000
1976.....	898,500,000
1977.....	948,000,000
1978.....	955,000,000
1979.....	1,036,000,000
1980.....	1,055,000,000
1981.....	1,170,000,000
1982.....	1,192,000,000
1983.....	1,197,000,000
1984.....	1,074,000,000
1985.....	1,189,000,000
1986.....	1,460,000,000
1987.....	1,570,000,000
1988.....	1,700,000,000
1989.....	2,080,000,000
1990.....	2,195,000,000
1991.....	2,410,000,000
1992.....	2,612,000,000
1993.....	2,775,000,000
1994.....	3,200,000,000
1995.....	3,600,000,000
1996.....	3,640,000,000
1997.....	2,977,000,000
1998.....	2,702,500,000
1999.....	3,191,000,000
2000.....	3,873,000,000
2001.....	4,135,000,000
2002.....	5,030,000,000

The National Cancer Act in December 1971, included a provision for the Director, NCI to submit an annual budget request directly to the President, with comment only by NIH and DHHS. This Bypass Budget was first submitted for 1973.



# Bypass Requests and Appropriations of the NCI 1973-2001





## Comparison of Dollars, Positions and Space Fiscal Years 1991-2000

Funds are obligations against the annual appropriation in millions of dollars

FTEs are the number of workyears for appointed employees of the NCI. A workyear equal 2080 hours.

195 contract staff are converted to NCI appointments.

Space is thousands of sq feet excluding the Frederick Cancer Research and Development Center.



## Personnel Resources Fiscal Years 1995-2000

---

Fiscal year	Full Time Appointment	Part Time Appointment	Training Fellows	Total Personnel Resources
1995	1767	483	1055	3305
1996	1841	460	960	3261
1997	1915	422	1023	3360
1998	1921	466	1124	3511
1999	1941	628	1060	3629
2000	2139	831	1202	4172